<SEC-DOCUMENT>0001493152-23-012377.txt : 20230414
<SEC-HEADER>0001493152-23-012377.hdr.sgml : 20230414
<ACCEPTANCE-DATETIME>20230414172114
ACCESSION NUMBER:		0001493152-23-012377
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230414
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230414
DATE AS OF CHANGE:		20230414

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioRestorative Therapies, Inc.
		CENTRAL INDEX KEY:			0001505497
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
		IRS NUMBER:				911835664
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37603
		FILM NUMBER:		23822104

	BUSINESS ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747
		BUSINESS PHONE:		(631) 760-8100

	MAIL ADDRESS:	
		STREET 1:		40 MARCUS DRIVE
		CITY:			MELVILLE
		STATE:			NY
		ZIP:			11747

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stem Cell Assurance, Inc.
		DATE OF NAME CHANGE:	20101110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:BRTX="http://biorestorative.com/20230414">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_BRTX_biorestorative.com_20230414 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20230414_20230414 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001505497 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:EntityCentralIndexKey">0001505497</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="brtx-20230414.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-04-14to2023-04-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001505497</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-14</xbrli:startDate>
        <xbrli:endDate>2023-04-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>WASHINGTON,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_908_edei--DocumentType_c20230414__20230414_zPSOK2lyGvIl"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of the</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report: <span id="xdx_906_edei--DocumentPeriodEndDate_c20230414__20230414_zJHayJ2rXZ3l"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">April 14, 2023</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Date
of earliest event reported)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityRegistrantName_c20230414__20230414_zsXGxplSUTfi"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:EntityRegistrantName">BIORESTORATIVE
THERAPIES, INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20230414__20230414_zfJTLdbLtXe3"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityFileNumber_c20230414__20230414_znEKVQ4njFB6"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:EntityFileNumber">001-37603</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20230414__20230414_z8Uv5m8mkl8l"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:EntityTaxIdentificationNumber">30-1341024</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or Other Jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    Incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    No.)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
                                            Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 100%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityAddressAddressLine1_c20230414__20230414_zmn3Yg9V5MJb"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:EntityAddressAddressLine1">40
    Marcus Drive</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20230414__20230414_zLc7Iy3kzYN7"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:EntityAddressCityOrTown">Melville</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressStateOrProvince_c20230414__20230414_zreP3Ggm5RTl"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityAddressPostalZipCode_c20230414__20230414_zgzB4UWZCmBj"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:EntityAddressPostalZipCode">11747</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of Principal Executive Offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code: <span style="text-decoration: underline"><span id="xdx_905_edei--CityAreaCode_c20230414__20230414_zb3awo9HFn9e"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:CityAreaCode">(631)</ix:nonNumeric></span> <span id="xdx_909_edei--LocalPhoneNumber_c20230414__20230414_z7D05pJzfTCl"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:LocalPhoneNumber">760-8100</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><span id="xdx_906_edei--WrittenCommunications_c20230414__20230414_zQvqDlGyDdQ"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_903_edei--SolicitingMaterial_c20230414__20230414_zKA4dPbQC5ld"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20230414__20230414_zTZuHSRFDAle"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20230414__20230414_z2313YpcQIr6"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></p></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></p></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20230414__20230414_zcOUvGsrvDLl"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:Security12bTitle">Common
    Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--TradingSymbol_c20230414__20230414_zIhOCGDhqak6"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" name="dei:TradingSymbol">BRTX</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_906_edei--SecurityExchangeName_c20230414__20230414_zt5yPG2Al9Tc"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span>
    Capital Market</span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20230414__20230414_zU1YDRolC176"><ix:nonNumeric contextRef="From2023-04-14to2023-04-14" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span>&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 14, 2023, BioRestorative Therapies, Inc. (the &#8220;Company&#8221;) entered into a Capital On Demand&#8482; Sales Agreement (the
&#8220;Sales Agreement&#8221;) with JonesTrading Institutional Services LLC (the &#8220;Agent&#8221;), pursuant to which the Company
may offer and sell, from time to time, through or to the Agent, shares of the Company&#8217;s common stock, par value $0.0001 per share,
having an aggregate offering price of up to $3.7 million (the &#8220;Shares&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is not obligated to sell any Shares under the Sales Agreement. Subject to the terms and conditions of the Sales Agreement, the
Agent will use commercially reasonable efforts, consistent with its normal trading and sales practices, to sell Shares from time to time
based upon the Company&#8217;s instructions, including any price, time or size limits or other customary parameters or conditions specified
by the Company. Under the Sales Agreement, the Agent may sell Shares by any method permitted by law deemed to be an &#8220;at the market
offering&#8221; under Rule 415(a)(4) under the Securities Act of 1933, as amended. The Company will pay the Agent a commission equal
to 3.0% of the gross sales price from each sale of Shares and provide the Agent with customary indemnification and contribution rights.
The Sales Agreement may be terminated by the Agent or the Company at any time upon notice to the other party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance and sale, if any, of the Shares by the Company under the Sales Agreement will be made pursuant to the Company&#8217;s effective
registration statement on Form S-3 (Registration Statement No. 333-269631) (as amended, the &#8220;Registration Statement&#8221;), filed
with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 7, 2023, and declared effective on February 14, 2023.
The offering is described in the Company&#8217;s Prospectus Supplement, dated April 14, 2023, as filed with the SEC on April 14, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing description of the Sales Agreement does not purport to be complete and is qualified in its entirety by reference to the full
text of the Sales Agreement, a copy of which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by
reference. The legal opinion of Certilman Balin Adler &amp; Hyman, LLP, counsel to the Company, relating to the validity of the Shares
being offered pursuant to the Sales Agreement is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein by
reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex1-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital On Demand&#8482; Sales Agreement, dated as of April 14, 2023, by and between BioRestorative Therapies, Inc. and JonesTrading Institutional Services LLC</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Certilman Balin Adler &amp; Hyman, LLP</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="ex5-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Certilman Balin Adler &amp; Hyman, LLP (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 3.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><b>BIORESTORATIVE THERAPIES, INC.</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    April 14, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Lance Alstodt</i>&#160;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
Alstodt</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
and CEO</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Wsq1hPAyKYksRCK6XXKMJd2R2e3vkXrLNiUaBobhnO8cIUKR01q3yHBaVgUcsOtb5RAqbJDRnNE7ss02BX8rvGjrWBk3vD8wI8+gZ5KJXCgvDNa7tlinEM2ncj6NZxDN0kRCuRPBV8/INLpG47RqQZkaSqaeNTrFrzHhoJ5kqHsNVUdkq8mkICfRKL8hjmQMe7qrB/HVQlFkIgiHCUTOdOu/NTfrqINVi53vsiP63+ADGgFJTA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
THERAPIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">($0.0001
par value per share)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
on Demand<FONT STYLE="font-weight: normal">&trade;</FONT> Sales Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
14, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JonesTrading
Institutional Services LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">211
East 43<SUP>rd</SUP> Street, 15<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), confirms its agreement (this &ldquo;<U>Agreement</U>&rdquo;)
with JonesTrading Institutional Services LLC (the &ldquo;<U>Agent</U>&rdquo;), as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Issuance and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject
to the conditions set forth herein, it may issue and sell through or to the Agent, as agent or principal, shares (the &ldquo;<U>Placement
Shares</U>&rdquo;) of common stock of the Company, $0.0001 par value per share (the &ldquo;<U>Common Stock</U>&rdquo;); <I>provided,
however</I>, that in no event shall the Company issue or sell, through or to Agent, Placement Shares for an aggregate gross sales proceeds
that would exceed (a) the dollar amount of shares of Common Stock registered on the Registration Statement (as defined below), (b) the
number of authorized but unissued shares of Common Stock, (c) the dollar amount of shares of Common Stock permitted to be sold under
Form S-3, including General Instruction I.B.6 of Form S-3, or (d) the dollar amount of shares of Common Stock for which the Company has
filed a Prospectus (as defined below) (the least of (a), (b), (c) and (d), the &ldquo;<U>Maximum Amount</U>&rdquo;). Notwithstanding
anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 1
on the amount of Placement Shares issued and sold under this Agreement shall be the sole responsibility of the Company and that Agent
shall have no obligation in connection with such compliance. The issuance and sale of Placement Shares hereunder will be effected pursuant
to the Registration Statement filed by the Company and declared effective by the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;),
although nothing in this Agreement shall be construed as requiring the Company to issue any Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date hereof, the Company has filed, in accordance with the provisions of the Securities Act of 1933, as amended, and the rules
and regulations thereunder (the &ldquo;<U>Securities Act</U>&rdquo;), with the Commission a registration statement on Form S-3 (333-269631),
including a base prospectus, relating to certain securities, including the Placement Shares to be issued from time to time by the Company,
and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions of the Securities
Exchange Act of 1934, as amended, and the rules and regulations thereunder (the &ldquo;<U>Exchange Act</U>&rdquo;). The Company has prepared
a prospectus supplement to the base prospectus included as part of the registration statement specifically relating to the Placement
Shares (the &ldquo;<U>Prospectus Supplement</U>&rdquo;). The Company will furnish to the Agent, for use by the Agent, copies of the base
prospectus included as part of such registration statement, as supplemented by Prospectus Supplement, relating to the Placement Shares.
Except where the context otherwise requires, such registration statement, and any post-effective amendment thereto, including all documents
filed as part thereof or incorporated by reference therein, and including any information contained in a Prospectus (as defined below)
subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement
pursuant to Rule 430B or 462(b) under the Securities Act or any subsequent registration statement on Form S-3 filed pursuant to Rule
415(a)(6) under the Securities Act by the Company to cover any Placement Shares, as a result of the end of the three-year period described
in Rule 415(a)(5) of the Securities Act, is herein called the &ldquo;<U>Registration Statement</U>.&rdquo; The base prospectus, including
all documents incorporated therein by reference, to the extent such information has not been superseded or modified in accordance with
Rule 412 under the Securities Act (as qualified by Rule 430B(g) of the Securities Act), included in the Registration Statement, as it
may be supplemented by one or more prospectus supplements, in the form in which such Prospectus Supplement has most recently been filed
by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any then issued Issuer Free Writing
Prospectus (defined below), is herein called the &ldquo;<U>Prospectus</U>.&rdquo; Any reference herein to the Registration Statement,
the Prospectus or any amendment or supplement thereto shall be deemed to refer to and include the documents incorporated by reference
therein, and any reference herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect
to the Registration Statement or the Prospectus shall be deemed to refer to and include the filing after the execution hereof of any
document with the Commission deemed to be incorporated by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
reference herein to the Registration Statement, the Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall
be deemed to refer to and include the documents, if any, incorporated by reference therein (the &ldquo;<U>Incorporated Documents</U>&rdquo;),
including, unless the context otherwise requires, the documents, if any, filed as exhibits to such Incorporated Documents. Any reference
herein to the terms &ldquo;amend,&rdquo; &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the Registration Statement,
the Prospectus Supplement, the Prospectus or any Issuer Free Writing Prospectus shall be deemed to refer to and include the filing of
any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the date of the Prospectus
or such Issuer Free Writing Prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all
references to the Registration Statement, the Prospectus or to any amendment or supplement thereto shall be deemed to include any copy
filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval system, or if applicable, the Interactive
Data Electronic Application system when used by the Commission (collectively, &ldquo;<U>EDGAR</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Placements</U>. Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a &ldquo;<U>Placement</U>&rdquo;),
it will notify the Agent by email notice (or other method mutually agreed to in writing by the Parties) of the number or dollar value
of Placement Shares to be sold, the time period during which sales are requested to be made, any limitation on the number of Placement
Shares that may be sold in any one Trading Day and any minimum price below which sales may not be made (a &ldquo;<U>Placement Notice</U>&rdquo;),
the form of which is attached hereto as Schedule 1. The Placement Notice shall originate from any of the individuals from the Company
set forth on Schedule 3 (with a copy to each of the other individuals from the Company listed on such schedule), and shall be addressed
to each of the individuals from the Agent set forth on Schedule 3, as such Schedule 3 may be amended from time to time. The Placement
Notice shall be effective unless and until (i) the Agent declines to accept the terms contained therein for any reason, in its sole discretion,
(ii) the entire amount of the Placement Shares to be sold thereunder have been sold, (iii) the Company suspends or terminates the Placement
Notice for any reason, in its sole discretion, (iv) the Company issues a subsequent Placement Notice with parameters superseding those
of the earlier dated Placement Notice, or (v) this Agreement has been terminated under the provisions of Section 12. The amount of any
discount, commission or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement Shares
shall be calculated in accordance with the terms set forth in Schedule 2. It is expressly acknowledged and agreed that neither the Company
nor the Agent will have any obligation whatsoever with respect to a Placement or any Placement Shares unless and until the Company delivers
a Placement Notice to the Agent and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then
only upon the terms specified therein and herein. In the event of a conflict between the terms of this Agreement and the terms of a Placement
Notice, the terms of the Placement Notice will control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Sale of Placement Shares by the Agent</U>. Subject to the provisions of <U>Section 5(a)</U>, the Agent, for the period specified in
the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable
state and federal laws, rules and regulations and the rules of The Nasdaq Stock Market LLC (the &ldquo;<U>Exchange</U>&rdquo;), to sell
the Placement Shares up to the amount specified in, and otherwise in accordance with the terms of such Placement Notice. The Agent will
provide written confirmation to the Company no later than the opening of the Trading Day immediately following the Trading Day on which
it has made sales of Placement Shares hereunder setting forth the number of Placement Shares sold on such day, the compensation payable
by the Company to the Agent pursuant to <U>Section 2</U> with respect to such sales, and the Net Proceeds (as defined below) payable
to the Company, with an itemization of the deductions made by the Agent (as set forth in <U>Section 5(b)</U>) from the gross proceeds
that it receives from such sales. Subject to the terms of the Placement Notice, the Agent may sell Placement Shares by any method permitted
by law deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Suspension of Sales</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the individuals
of the other party set forth on Schedule 3, if receipt of such correspondence is actually acknowledged by any of the individuals to whom
the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable facsimile transmission or email correspondence
to each of the individuals of the other party set forth on Schedule 3), suspend any sale of Placement Shares; <I>provided, however</I>,
that such suspension shall not affect or impair any party&rsquo;s obligations with respect to any Placement Shares sold hereunder prior
to the receipt of such notice. Each party agrees that no such notice under this Section 4 shall be effective against any other party
unless it is made to one of the individuals named on Schedule 3 hereto as associated with such other party, as such Schedule may be amended
in writing from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>Sale and Delivery to the Agent; Settlement</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Sale of Placement Shares</U><I>. </I>On the basis of the representations and warranties herein contained and subject to the terms
and conditions herein set forth, upon the Agent&rsquo;s acceptance of the terms of a Placement Notice, and unless the sale of the Placement
Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement, the Agent,
for the period specified in the Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and
sales practices to sell such Placement Shares up to the amount specified in such Placement Notice, and otherwise in accordance with the
terms of such Placement Notice. The Company acknowledges and agrees that (i) there can be no assurance that the Agent will be successful
in selling Placement Shares, (ii) the Agent will incur no liability or obligation to the Company or any other person or entity if it
does not sell Placement Shares for any reason other than a failure by the Agent to use its commercially reasonable efforts consistent
with its normal trading and sales practices and applicable law and regulations to sell such Placement Shares as required under this Agreement
and (iii) the Agent shall be under no obligation to purchase Placement Shares on a principal basis pursuant to this Agreement, except
as otherwise agreed by the Agent and the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Settlement of Placement Shares</U><I>. </I>Unless otherwise specified in the applicable Placement Notice, settlement for sales of
Placement Shares will occur on the second (2<SUP>nd</SUP>) Trading Day (or such earlier day as is industry practice for regular-way trading)
following the date on which such sales are made (each, a &ldquo;<U>Settlement Date</U>&rdquo;). The amount of proceeds to be delivered
to the Company on a Settlement Date against receipt of the Placement Shares sold (the &ldquo;<U>Net Proceeds</U>&rdquo;) will be equal
to the aggregate sales price received by the Agent, after deduction for (i) the Agent&rsquo;s commission, discount or other compensation
for such sales payable by the Company pursuant to Section 2 hereof, and (ii) any transaction fees imposed by any governmental or self-regulatory
organization in respect of such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Delivery of Placement Shares</U>. On or before each Settlement Date, the Company will, or will cause its transfer agent to, electronically
transfer the Placement Shares being sold by crediting the Agent&rsquo;s or its designee&rsquo;s account (provided the Agent shall have
given the Company written notice of such designee at least one Trading Day prior to the Settlement Date) at The Depository Trust Company
through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually agreed upon by the parties
hereto which in all cases shall be freely tradable, transferable, registered shares in good deliverable form. On each Settlement Date,
the Agent will deliver the related Net Proceeds in same day funds to an account designated by the Company on, or prior to, the Settlement
Date. The Company agrees that if the Company, or its transfer agent (if applicable), defaults in its obligation to deliver Placement
Shares on a Settlement Date through no fault of the Agent, the Company agrees that in addition to and in no way limiting the rights and
obligations set forth in Section 10(a) hereto, it will (i) hold the Agent harmless against any loss, claim, damage, or reasonable and
documented expense (including reasonable and documented legal fees and expenses), as incurred, arising out of or in connection with such
default by the Company or its transfer agent (if applicable) and (ii) pay to the Agent (without duplication) any commission, discount,
or other compensation to which it would otherwise have been entitled absent such default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Limitations on Offering Size</U><I>. </I>Under no circumstances shall the Company cause or request the offer or sale of any Placement
Shares if, after giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant
to this Agreement would exceed the lesser of (A) together with all sales of Placement Shares under this Agreement, the Maximum Amount
and (B) the amount authorized from time to time to be issued and sold under this Agreement by the Company&rsquo;s board of directors,
a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances
shall the Company cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum
price authorized from time to time by the Company&rsquo;s board of directors, duly authorized committee thereof or a duly authorized
executive committee, and notified to the Agent in writing. Further, under no circumstances shall the Company cause or permit the aggregate
gross sales proceeds of Placement Shares sold pursuant to this Agreement to exceed the Maximum Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Representations and Warranties of the Company</U>. Except as disclosed in the Registration Statement or Prospectus (including the
Incorporated Documents), the Company represents and warrants to, and agrees with the Agent that as of the date of this Agreement and
as of each Applicable Time (as defined below), unless such representation, warranty or agreement specifies otherwise:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement and Prospectus</U>. As of the date of this Agreement, the Company and the transactions contemplated by this
Agreement meet the requirements for and comply with the conditions for the use of Form S-3 under the Securities Act. The Registration
Statement has been or will be filed with the Commission and has been or will be declared effective by the Commission under the Securities
Act prior to the issuance of any Placement Notice by the Company. The Prospectus Supplement will name Agent as agent, in the section
entitled &ldquo;Plan of Distribution.&rdquo; The Company has not received, and has no notice of, any order of the Commission preventing
or suspending the use of the Registration Statement, or threatening or instituting proceedings for that purpose. The Registration Statement
and the offer and sale of Placement Shares as contemplated hereby meet the requirements of Rule 415 under the Securities Act and comply
in all material respects with said Rule. Any statutes, regulations, contracts or other documents that are required to be described in
the Registration Statement or the Prospectus or to be filed as exhibits to the Registration Statement have been or will be so described
or filed. Copies of the Registration Statement, the Prospectus, and any such amendments or supplements and all documents incorporated
by reference therein that were filed with the Commission on or prior to the date of this Agreement have been delivered, or are available
through EDGAR, to the Agent and its counsel. The Company has not distributed and, prior to the later to occur of each Settlement Date
and completion of the distribution of the Placement Shares, will not distribute any offering material in connection with the offering
or sale of the Placement Shares other than the Registration Statement and the Prospectus and any Issuer Free Writing Prospectus to which
the Agent has consented. The Company has taken no action designed to, or likely to have the effect of, terminating the registration of
the Common Stock under the Exchange Act, delisting the Common Stock from the Exchange, nor has the Company received any notification
that the Commission or the Exchange is contemplating terminating such registration or listing. To the Company&rsquo;s knowledge, it is
in compliance with all applicable listing requirements of the Exchange. The Company has no reason to believe that it will not in the
foreseeable future continue to be in compliance with all such listing and maintenance requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>No Misstatement or Omission</U>. The Registration Statement, when it became or becomes effective, and the Prospectus, and any amendment
or supplement thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects
with the requirements of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date,
will conform in all material respects with the requirements of the Securities Act. The Registration Statement, when it became or becomes
effective, did not, and will not, contain an untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein not misleading. The Prospectus and any amendment or supplement thereto, on the date
thereof and at each Applicable Time (defined below), did not and will not include an untrue statement of a material fact or omit to state
a material fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. The
documents incorporated by reference in the Prospectus did not, and any further documents filed and incorporated by reference therein
will not, when filed with the Commission, contain an untrue statement of a material fact or omit to state a material fact required to
be stated in such document or necessary to make the statements in such document, in light of the circumstances under which they were
made, not misleading. The foregoing shall not apply to statements in, or omissions from, any such document made in reliance upon, and
in conformity with, information furnished to the Company by or on behalf of Agent specifically for use in the preparation thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Conformity with Securities Act and Exchange Act</U>. The Registration Statement, the Prospectus, any Issuer Free Writing Prospectus
or any amendment or supplement thereto, and the Incorporated Documents, when such documents were or are filed with the Commission under
the Securities Act or the Exchange Act or became or become effective under the Securities Act, as the case may be, conformed and will
conform in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Financial Information</U>. The financial statements of the Company included or incorporated by reference in the Registration Statement,
the Prospectus and the Issuer Free Writing Prospectuses, if any, together with the related notes and schedules, present fairly, in all
material respects, the financial position of the Company and the Subsidiaries (as defined below) as of the dates indicated and the results
of operations, cash flows and changes in stockholders&rsquo; equity of the Company and the Subsidiaries for the periods specified (subject,
in the case of unaudited interim financial statements, to normal year-end audit adjustments) and have been prepared in compliance with
the requirements of the Securities Act and Exchange Act and in conformity with GAAP (as defined below) applied on a consistent basis
(except for (i) such adjustments to accounting standards and practices as are noted therein, (ii) in the case of unaudited interim financial
statements, to the extent such financial statements may not include footnotes required by GAAP or may be condensed or summary statements
and (iii) such adjustments which will not be material, either individually or in the aggregate) during the periods involved. The summary
and selected financial data with respect to the Company and the Subsidiaries contained or incorporated by reference in the Registration
Statement, the Prospectus and the Issuer Free Writing Prospectuses, if any, fairly present in all material respects the information shown
therein as of the respective dates and for the respective periods specified and are derived from the financial statements set forth in
the Registration Statement and the Prospectus and the other books and records of the Company. There are no financial statements that
are required to be included or incorporated by reference in the Registration Statement, or the Prospectus that are not included or incorporated
by reference as required; the Company and the Subsidiaries do not have any material liabilities or obligations, direct or contingent
(including any off-balance sheet obligations), not described in the Registration Statement (excluding the exhibits thereto), and the
Prospectus. All disclosures contained or incorporated by reference in the Registration Statement, the Prospectus and the Issuer Free
Writing Prospectuses, if any, regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined by the rules and regulations
of the Commission) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities
Act, to the extent applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Conformity with EDGAR Filing</U>. The Prospectus delivered to the Agent for use in connection with the sale of the Placement Shares
pursuant to this Agreement will be identical to the versions of the Prospectus created to be transmitted to the Commission for filing
via EDGAR, except to the extent permitted by Regulation S-T.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Organization</U>. The Company and its Subsidiaries, if any, are, and will be, duly organized, validly existing as a corporation and
in good standing under the laws of their respective jurisdictions of organization. Each of the Company and the Subsidiaries is duly licensed
or qualified as a foreign corporation for transaction of business and in good standing under the laws of each other jurisdiction in which
its ownership or lease of property or the conduct of its business requires such license or qualification, and has all corporate power
and authority necessary to own or hold its properties and to conduct its business as described in the Registration Statement and the
Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or
in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the
assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders&rsquo; equity or results
of operations of the Company and the Subsidiaries taken as a whole, or prevent or materially interfere with consummation of the transactions
contemplated hereby (a &ldquo;<U>Material Adverse Effect</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Subsidiaries</U>. The Company&rsquo;s only Subsidiaries, if any, are set forth on Exhibit 21.1 to the Company&rsquo;s Annual Report
on Form 10-K for the most recently ended fiscal year. The Company owns directly or indirectly, all of the equity interests of the Subsidiaries
free and clear of any lien, charge, security interest, encumbrance, right of first refusal or other restriction, and all the equity interests
of the Subsidiaries are validly issued and are fully paid, nonassessable and free of preemptive and similar rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>No Violation or Default</U>. Neither the Company nor any Subsidiary is (i) in violation of its charter or by-laws or similar organizational
documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in
the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement
or other agreement or instrument to which the Company or any Subsidiary is a party or by which the Company or any Subsidiary is bound
or to which any of the property or assets of the Company or any Subsidiary is subject; or (iii) in violation of any law or statute or
any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of each
of clauses (ii) and (iii) above, for any such violation or default that would not, individually or in the aggregate, have a Material
Adverse Effect. To the Company&rsquo;s knowledge, no other party under any material contract or other agreement to which it or any Subsidiary
is a party is in default in any respect thereunder where such default would have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>No Material Adverse Effect</U>. Subsequent to the latest date of which information is given in the Registration Statement, the Prospectus
and the Issuer Free Writing Prospectuses, if any, (including any document deemed incorporated by reference therein), there has not been
(i) any Material Adverse Effect or the occurrence of any development that the Company reasonably expects will result in a Material Adverse
Effect, (ii) any transaction which is material to the Company and the Subsidiaries taken as a whole, (iii) any obligation or liability,
direct or contingent (including any off-balance sheet obligations), incurred by the Company or the Subsidiaries which is material to
the Company and the Subsidiaries taken as a whole, (iv) any material change in the capital stock or outstanding long-term indebtedness
of the Company or the Subsidiaries (other than (A) the grant of awards under equity incentive plans, (B) changes in the number of shares
of outstanding Common Stock due to exercise or conversion of securities exercisable for or convertible into Common Stock outstanding
as of the date of this Agreement, (C) any repurchase of capital stock of the Company, (D) as a result of the sale of Placement Shares
or (E) other than as publicly reported or announced) or (v) any dividend or distribution of any kind declared, paid or made on the capital
stock of the Company or any Subsidiary, other than in each case above in the ordinary course of business or as otherwise disclosed in
the Registration Statement or Prospectus (including any document deemed incorporated by reference therein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Capitalization</U>. The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid and
non-assessable and, other than as disclosed in the Registration Statement or the Prospectus, are not subject to any preemptive rights,
rights of first refusal or similar rights. The Company has an authorized, issued and outstanding capitalization as set forth in the Registration
Statement and the Prospectus as of the dates referred to therein (other than the grant of options and restricted stock units under the
Company&rsquo;s existing stock incentive plans, or changes in the number of outstanding shares of Common Stock of the Company due to
the issuance of shares upon the exercise or conversion of securities exercisable for, or convertible into, Common Stock outstanding on
the date hereof) and such authorized capital stock conforms in all material respects to the description thereof set forth in the Registration
Statement and the Prospectus. The description of the securities of the Company in the Registration Statement and the Prospectus is complete
and accurate in all material respects. Except as disclosed in the Registration Statement or the Prospectus, as of the date referred to
therein, the Company does not have outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities
or obligations convertible into, or exchangeable for, or any contracts or commitments to issue or sell, any shares of capital stock or
other securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Authorization; Enforceability</U>. The Company has full legal right, power and authority to enter into this Agreement and perform
the transactions contemplated hereby. This Agreement has been duly authorized, executed and delivered by the Company and is a legal,
valid and binding agreement of the Company enforceable in accordance with its terms, except to the extent that enforceability may be
limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights generally and by general
equitable principles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Authorization of Placement Shares</U>. The Placement Shares, when issued and delivered pursuant to the terms approved by the board
of directors of the Company or a duly authorized committee thereof, against payment therefor as provided herein, will be duly authorized,
validly issued and fully paid and non-assessable, free and clear of any pledge, lien, encumbrance, security interest or other claim,
including any statutory or contractual preemptive rights, resale rights, rights of first refusal or other similar rights, and will be
registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when issued, will conform in all material respects to the
description thereof set forth in or incorporated into the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>No Consents Required</U>. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority having jurisdiction over the Company is required for the execution, delivery and performance
by the Company this Agreement, the issuance and sale by the Company of the Placement Shares, except for such consents, approvals, authorizations,
orders and registrations or qualifications as may been obtained or be required under applicable state securities laws or by the by-laws
and rules of the Financial Industry Regulatory Authority (&ldquo;<U>FINRA</U>&rdquo;) or the Exchange in connection with the sale of
the Placement Shares by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>No Preferential Rights</U>. (i) No person, as such term is defined in Rule 1-02 of Regulation S-X promulgated under the Securities
Act (each, a &ldquo;<U>Person</U>&rdquo;), has the right, contractual or otherwise, to cause the Company to issue or sell to such Person
any Common Stock or shares of any other capital stock or other securities of the Company (other than upon the exercise of options or
warrants to purchase Common Stock, the vesting of restricted stock units or the conversion of shares of preferred stock), (ii) no Person
has any preemptive rights, resale rights, rights of first refusal, or any other rights (whether pursuant to a &ldquo;poison pill&rdquo;
provision or otherwise) to purchase any Common Stock or shares of any other capital stock or other securities of the Company, (iii) no
Person has the right to act as an underwriter or as a financial advisor to the Company in connection with the offer and sale of the Placement
Shares, and (iv) no Person has the right, contractual or otherwise, to require the Company to register under the Securities Act any Common
Stock or shares of any other capital stock or other securities of the Company, or to include any such shares or other securities in the
Registration Statement or the offering contemplated thereby, whether as a result of the filing or effectiveness of the Registration Statement
or the sale of the Placement Shares as contemplated thereby or otherwise, except for such rights as have been or will be duly waived
on or prior to the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Independent Public Accountant</U>. The Company&rsquo;s accountants, whose report on the financial statements of the Company is filed
with the Commission as part of the Company&rsquo;s most recent Annual Report on Form 10-K filed with the Commission and incorporated
by reference into the Registration Statement and the Prospectus, are and, during the periods covered by their report, were an independent
registered public accounting firm with respect to the Company within the meaning of the Securities Act and the Public Company Accounting
Oversight Board (United States). To the Company&rsquo;s knowledge, the Company&rsquo;s accountants are not in violation of the auditor
independence requirements of the Sarbanes-Oxley Act of 2002 (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;) with respect to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Enforceability of Agreements</U>. All agreements between the Company and third parties expressly referenced in the Prospectus, other
than such agreements that have expired by their terms or the termination of which is disclosed in documents filed by the Company on EDGAR,
are legal, valid and binding obligations of the Company enforceable in accordance with their respective terms, except to the extent that
(i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors&rsquo; rights
generally and by general equitable principles and (ii) the indemnification provisions of certain agreements may be limited by federal
or state securities laws or public policy considerations in respect thereof; except for any unenforceability that, individually or in
the aggregate, would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>No Litigation</U>. There are no legal, governmental or regulatory actions, suits or proceedings pending, nor, to the Company&rsquo;s
knowledge, any legal, governmental or regulatory investigations, to which the Company or any Subsidiary is a party or to which any property
of the Company or any Subsidiary is the subject that, individually or in the aggregate, if determined adversely to the Company or any
Subsidiary, would have a Material Adverse Effect or materially and adversely affect the ability of the Company to perform its obligations
under this Agreement; to the Company&rsquo;s knowledge, no such actions, suits or proceedings are threatened or contemplated by any governmental
or regulatory authority or threatened by others that, individually or in the aggregate, if determined adversely to the Company or any
Subsidiary, would reasonably be expected to have a Material Adverse Effect; and (i) to the Company&rsquo;s knowledge, there are no current
or pending legal, governmental or regulatory audits or investigations, actions, suits or proceedings that are required under the Securities
Act to be described in the Prospectus that are not so described; and (ii) there are no contracts or other documents that are required
under the Securities Act to be filed as exhibits to the Registration Statement that are not so filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Licenses and Permits</U>. The Company and the Subsidiaries have made all filings, applications and submissions required by, possesses
and is operating in compliance with, all approvals, licenses, certificates, consents, orders, permits and other authorizations issued
by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities
(including, without limitation, the United States Food and Drug Administration (the &ldquo;<U>FDA</U>&rdquo;), the United States Drug
Enforcement Administration or any other foreign, federal, state, provincial, court or local government or regulatory authorities including
self-regulatory organizations engaged in the regulation of clinical trials, pharmaceuticals, biologics or biohazardous substances or
materials) that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses
as described in the Registration Statement and the Prospectus (the &ldquo;<U>Permits</U>&rdquo;), except where the failure to possess,
obtain or make the same would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor any Subsidiary
has received written notice of any proceeding relating to revocation or modification of any such Permit or has any reason to believe
that such Permit will not be renewed in the ordinary course, except where the failure to obtain any such renewal would not, individually
or in the aggregate, have a Material Adverse Effect. To the extent required by applicable laws and regulations of the FDA, the Company
or the applicable Subsidiary has submitted to the FDA an Investigational Device Exemption Application or amendment or supplement thereto
for each clinical trial it has conducted or sponsored or is conducting or sponsoring; all such submissions were in material compliance
with applicable laws and rules and regulations when submitted and no material deficiencies have been asserted by the FDA with respect
to any such submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Regulatory Filings</U>. The Company has not failed to file with the applicable regulatory authorities (including, without limitation,
the FDA, or any foreign, federal, state, provincial or local Governmental Authority performing functions similar to those performed by
the FDA) any required filing, declaration, listing, registration, report or submission, except for such failures that, individually or
in the aggregate, would not reasonably be expected to have a Material Adverse Effect; all such filings, declarations, listings, registrations,
reports or submissions were in compliance with applicable laws when filed and no deficiencies have been asserted by any applicable regulatory
authority with respect to any such filings, declarations, listings, registrations, reports or submissions, except for any deficiencies
that, individually or in the aggregate, would not have a Material Adverse Effect. The Company has operated and currently is, in all material
respects, in compliance with the United States Federal Food, Drug, and Cosmetic Act, all applicable rules and regulations of the FDA
and other federal, state, local and foreign Governmental Authority exercising comparable authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
<U>Compliance with Applicable Laws</U>. The Company and the Subsidiaries: (A) are and at all times have been in material compliance with
all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured
or distributed by the Company or the Subsidiaries (&ldquo;<U>Applicable Laws</U>&rdquo;), (b) have not received any Form 483 from the
FDA, notice of adverse finding, warning letter, or other written correspondence or notice from the FDA, the European Medicines Agency
(the &ldquo;<U>EMA</U>&rdquo;), or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting
material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements
or amendments thereto required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;), which would, individually or in the
aggregate, result in a Material Adverse Effect; (C) possess all material Authorizations and such Authorizations are valid and in full
force and effect and neither the Company nor the Subsidiaries is in material violation of any term of any such Authorizations; (D) have
not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
from the FDA, the EMA, or any other federal, state, local or foreign governmental or regulatory authority or third party alleging that
any Company product, operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that
the FDA, the EMA, or any other federal, state, local or foreign governmental or regulatory authority or third party is considering any
such claim, litigation, arbitration, action, suit, investigation or proceeding against the Company; (E) have not received written notice
that the FDA, EMA, or any other federal, state, local or foreign governmental or regulatory authority has taken, is taking or intends
to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA, EMA, or any other federal,
state, local or foreign governmental or regulatory authority is considering such action; and (F) have filed, obtained, maintained or
submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required
by any Applicable Laws or Authorizations except where the failure to file such reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments would not result in a Material Adverse Effect, and that all such reports, documents,
forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the
date filed (or were corrected or supplemented by a subsequent submission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
<U>Compliance Program.</U> The Company has established and administers a compliance program applicable to the Company, to assist the
Company and the directors, officers and employees of the Company in complying with applicable regulatory guidelines (including, without
limitation, those administered by the FDA, the EMA, and any other foreign, federal, state or local governmental or regulatory authority
performing functions similar to those performed by the FDA or EMA); except where such noncompliance would not reasonably be expected
to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
<U>Clinical Studies</U>. The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company
were, and, if still pending are, to the Company&rsquo;s knowledge, being conducted in all material respects in compliance with all Applicable
Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study
and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions
of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate
and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no
knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial
or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in
which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any
other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical
trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of
which are referred to in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
<U>Market Capitalization</U>. At the time the Registration Statement was or will be declared effective, and at the time the Company&rsquo;s
most recent Annual Report on Form 10-K was filed with the Commission, the Company met or will meet the then applicable requirements for
the use of Form S-3 under the Securities Act, including, but not limited to, General Instruction I.B.6 of Form S-3, if applicable. The
aggregate market value of the outstanding voting and non-voting common equity (as defined in Securities Act Rule 405) of the Company
held by persons other than affiliates of the Company (pursuant to Securities Act Rule 144, those that directly, or indirectly through
one or more intermediaries, control, or are controlled by, or are under common control with, the Company) (the &ldquo;<U>Non-Affiliate
Shares</U>&rdquo;), was equal to $10,842,115 (calculated by multiplying (x) the highest price at which the common equity of the Company
closed on the Exchange on March 2, 2023 times (y) the number of Non-Affiliate Shares). The Company is not a shell company (as defined
in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously and if it has been
a shell company at any time previously, has filed current Form 10 information (as defined in Instruction I.B.6 of Form S-3) with the
Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
<U>No Material Defaults</U>. Neither the Company nor any Subsidiary has defaulted on any installment on indebtedness for borrowed money
or on any rental on one or more long-term leases, which defaults, individually or in the aggregate, would reasonably be expected to have
a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing
of its last Annual Report on Form 10-K, indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred
stock or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which
defaults, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
<U>Certain Market Activities</U>. Neither the Company, any Subsidiary nor any of its directors or officers or, to the Company&rsquo;s
knowledge, controlling persons has taken, directly or indirectly, any action designed, or that has constituted or would reasonably be
expected to cause or result in, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
<U>Broker/Dealer Relationships</U>. Neither the Company, any of its Subsidiaries, nor any of the Company&rsquo;s affiliates (i) is required
to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo; in accordance with the provisions of the Exchange Act or (ii) directly
or indirectly through one or more intermediaries, controls or is a &ldquo;person associated with a member&rdquo; or &ldquo;associated
person of a member&rdquo; (within the meaning set forth in the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)
<U>No Reliance</U>. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax or accounting advice
in connection with the offering and sale of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)
<U>Taxes</U>. The Company and the Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to file or pay would not have a Material Adverse Effect. Except as otherwise disclosed
in or contemplated by the Registration Statement or the Prospectus, no tax deficiency has been determined adversely to the Company or
any Subsidiary which has had, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal,
state or other governmental tax deficiency, penalty or assessment which has been asserted or threatened against it which would reasonably
be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)
<U>Title to Real and Personal Property</U>. The Company and the Subsidiaries have good and marketable title to all items of real property
owned by them and good and valid title to all personal property described in the Registration Statement or Prospectus as being owned
by them that are material to the businesses of the Company or such Subsidiary, in each case free and clear of all liens, encumbrances
and claims, except those that (i) do not materially interfere with the use made and proposed to be made of such property by the Company
and the Subsidiaries or (ii) would not, individually or in the aggregate, have a Material Adverse Effect. Any real property described
in the Registration Statement or Prospectus as being leased by the Company and the Subsidiaries is held by them under valid, existing
and enforceable leases, except those that (A) do not materially interfere with the use made or proposed to be made of such property by
the Company or the Subsidiaries or (B) would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)
<U>Intellectual Property</U>. The Company and the Subsidiaries own or possess enforceable rights to use all patents, patent applications,
trademarks (both registered and unregistered), service marks, trade names, trademark registrations, service mark registrations, copyrights,
licenses and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems
or procedures) (collectively, the &ldquo;<U>Intellectual Property</U>&rdquo;), necessary for the conduct of their respective businesses
as conducted as of the date hereof, except to the extent that the failure to own or possess adequate rights to use such Intellectual
Property would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor
any Subsidiary has received any written notice of any claim of infringement or conflict which asserted Intellectual Property rights of
others, which infringement or conflict, if the subject of an unfavorable decision, would result in a Material Adverse Effect; there are
no pending, or to the Company&rsquo;s knowledge, threatened judicial proceedings or interference proceedings challenging the Company&rsquo;s
or any Subsidiary&rsquo;s rights in or to or the validity of the scope of any of the Company&rsquo;s or any Subsidiary&rsquo;s patents,
patent applications or proprietary information, except if such proceedings would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)
<U>Environmental Laws</U>. Except as set forth in the Registration Statement or the Prospectus, the Company and the Subsidiaries (i)
are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, decisions and orders relating
to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(collectively, &ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received and are in compliance with all permits, licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses as described in the Registration
Statement and the Prospectus; and (iii) have not received notice of any actual or potential liability for the investigation or remediation
of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, except, in the case of any of clauses
(i), (ii) or (iii) above, for any such failure to comply or failure to receive required permits, licenses, other approvals or liability
as would not, individually or in the aggregate, have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)
<U>Disclosure Controls</U>. The Company maintains systems of internal controls designed to provide reasonable assurance that (i) transactions
are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. The Company is not aware of any material weaknesses in its internal control over financial reporting (other than as
set forth in the Prospectus or the Incorporated Documents). Since the date of the latest audited financial statements of the Company
included in the Prospectus, there has been no change in the Company&rsquo;s internal control over financial reporting that has materially
affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting (other than as
set forth in the Prospectus). The Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15
and 15d-15) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the
Company is made known to the certifying officers by others within those entities, particularly during the period in which the Company&rsquo;s
Annual Report on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, is being prepared. The Company&rsquo;s certifying officers
have evaluated the effectiveness of the Company&rsquo;s disclosure controls and procedures as of a date within 90 days prior to the filing
date of the Form 10-K for the fiscal year most recently ended (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented
in its Form 10-K for the fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant
changes in the Company&rsquo;s internal controls or, to the Company&rsquo;s knowledge, in other factors that would be reasonably expected
to significantly affect the Company&rsquo;s internal controls. To the knowledge of the Company, the Company&rsquo;s &ldquo;internal controls
over financial reporting&rdquo; and &ldquo;disclosure controls and procedures&rdquo; are effective (other than as set forth in the Incorporated
Documents).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)
<U>Sarbanes-Oxley</U>. There has been no failure on the part of the Company or, any of the Company&rsquo;s directors or officers, in
their capacities as such, to comply with any applicable provisions of the Sarbanes-Oxley Act and the applicable rules and regulations
promulgated thereunder in all material respects. Each of the principal executive officer and the principal financial officer of the Company
(or each former principal executive officer of the Company and each former principal financial officer of the Company as applicable)
has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act with respect to all reports, schedules, forms,
statements and other documents required to be filed by it or furnished by it to the Commission during the 12 months prior to the date
of this Agreement. For purposes of the preceding sentence, &ldquo;principal executive officer&rdquo; and &ldquo;principal financial officer&rdquo;
shall have the meanings given to such terms in the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)
<U>Finder&rsquo;s Fees</U>. Neither the Company nor any Subsidiary has incurred any liability for any finder&rsquo;s fees, brokerage
commissions or similar payments in connection with the transactions herein contemplated, except as may otherwise exist with respect to
Agent pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
<U>Labor Disputes</U>. No labor disturbance by or dispute with employees of the Company or any Subsidiary exists or, to the knowledge
of the Company, is threatened which would have a Material Adverse Effect</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)
<U>Investment Company Act</U>. Neither the Company or any Subsidiary is or, after giving effect to the offering and sale of the Placement
Shares, will it be an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company,&rdquo;
as such terms are defined in the Investment Company Act of 1940, as amended (the &ldquo;<U>Investment Company Act</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)
<U>Operations</U>. The operations of the Company and the Subsidiaries are and have been conducted at all times in compliance with applicable
financial record keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions to which the Company or the Subsidiaries are subject, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the
&ldquo;<U>Money Laundering Laws</U>&rdquo;), except as would not have a Material Adverse Effect; and no action, suit or proceeding by
or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect
to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)
<U>Off-Balance Sheet Arrangements</U>. There are no transactions, arrangements and other relationships between and/or among the Company,
and/or, to the knowledge of the Company, any of its affiliates and any unconsolidated entity, including, but not limited to, any structured
finance, special purpose or limited purpose entity (each, an &ldquo;<U>Off Balance Sheet Transaction</U>&rdquo;) that would reasonably
be expected to affect materially the Company&rsquo;s liquidity or the availability of or requirements for its capital resources required
to be described in the Prospectus which have not been described as required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)
<U>Other Agreements</U>. The Company is not a party to any agreement with an agent or underwriter for any other &ldquo;at the market&rdquo;
or continuous equity transaction other than this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)
<U>ERISA</U>. To the knowledge of the Company, each material employee benefit plan, within the meaning of Section 3(3) of the Employee
Retirement Income Security Act of 1974, as amended (&ldquo;<U>ERISA</U>&rdquo;), that is maintained, administered or contributed to by
the Company or any of its affiliates for employees or former employees of the Company and the Subsidiaries has been maintained in material
compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to
ERISA and the Internal Revenue Code of 1986, as amended (the &ldquo;<U>Code</U>&rdquo;); no prohibited transaction, within the meaning
of Section 406 of ERISA or Section 4975 of the Code, has occurred which would result in a material liability to the Company with respect
to any such plan excluding transactions effected pursuant to a statutory or administrative exemption; and for each such plan that is
subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no &ldquo;accumulated funding deficiency&rdquo; as defined
in Section 412 of the Code has been incurred, whether or not waived, and the fair market value of the assets of each such plan (excluding
for these purposes accrued but unpaid contributions) exceeds the present value of all benefits accrued under such plan determined using
reasonable actuarial assumptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)
<U>Forward Looking Statements</U>. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section
21E of the Exchange Act) (a &ldquo;<U>Forward Looking Statement</U>&rdquo;) contained in the Registration Statement and the Prospectus
has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)
<U>Agent Purchases</U>. The Company acknowledges and agrees that Agent has informed the Company that the Agent may, to the extent permitted
under the Securities Act and the Exchange Act, purchase and sell Common Stock for its own account while this Agreement is in effect,
provided, that (i) no such purchase or sales shall take place while a Placement Notice is in effect (except to the extent the Agent may
engage in sales of Placement Shares purchased or deemed purchased from the Company as a &ldquo;riskless principal&rdquo; or in a similar
capacity) and (ii) the Company shall not be deemed to have authorized or consented to any such purchases or sales by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)
<U>Margin Rules</U>. Neither the issuance, sale and delivery of the Placement Shares nor the application of the proceeds thereof by the
Company as described in the Registration Statement and the Prospectus will violate Regulation T, U or X of the Board of Governors of
the Federal Reserve System or any other regulation of such Board of Governors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)
<U>Insurance</U>. The Company and the Subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as the
Company and the Subsidiaries reasonably believe is adequate for the conduct of their business and as is customary for companies of similar
size engaged in similar businesses in similar industries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)
<U>No Improper Practices</U>. (i) Neither the Company nor, to the Company&rsquo;s knowledge, the Subsidiaries nor any of their respective
executive officers has, in the past five years, made any unlawful contributions to any candidate for any political office (or failed
fully to disclose any contribution in violation of law) or made any contribution or other payment to any official of, or candidate for,
any federal, state, municipal, or foreign office or other person charged with similar public or quasi-public duty in violation of any
law or of the character required to be disclosed in the Prospectus; (ii) no relationship, direct or indirect, exists between or among
the Company or, to the Company&rsquo;s knowledge, the Subsidiaries or any affiliate of any of them, on the one hand, and the directors,
officers and stockholders of the Company or, to the Company&rsquo;s knowledge, the Subsidiaries, on the other hand, that is required
by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described; (iii) no relationship,
direct or indirect, exists between or among the Company or the Subsidiaries or, to the Company&rsquo;s knowledge, any affiliate of them,
on the one hand, and the directors, officers or stockholders of the Company or, to the Company&rsquo;s knowledge, the Subsidiaries, on
the other hand, that is required by the rules of FINRA to be described in the Registration Statement and the Prospectus that is not so
described; (iv) there are no material outstanding loans or advances or material guarantees of indebtedness by the Company or, to the
Company&rsquo;s knowledge, the Subsidiaries to or for the benefit of any of their respective officers or directors or any of the members
of the families of any of them; (v) the Company has not offered, or caused any placement agent to offer, Common Stock to any person with
the intent to influence unlawfully (A) a customer or supplier of the Company or the Subsidiaries to alter the customer&rsquo;s or supplier&rsquo;s
level or type of business with the Company or the Subsidiaries or (B) a trade journalist or publication to write or publish favorable
information about the Company or the Subsidiaries or any of their respective products or services, and, (vi) neither the Company nor
the Subsidiaries nor, to the Company&rsquo;s knowledge, any employee or agent of the Company or the Subsidiaries has made any payment
of funds of the Company or the Subsidiaries or received or retained any funds in violation of any law, rule or regulation (including,
without limitation, the Foreign Corrupt Practices Act of 1977), which payment, receipt or retention of funds is of a character required
to be disclosed in the Registration Statement or the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)
<U>Status Under the Securities Act</U>. The Company was not and is not an ineligible issuer as defined in Rule 405 under the Securities
Act at the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)
<U>No Misstatement or Omission in an Issuer Free Writing Prospectus</U>. Each Issuer Free Writing Prospectus, as of its issue date and
as of each Applicable Time (as defined below), did not, does not and will not, through the completion of the Placement for which such
Issuer Free Writing Prospectus is used or deemed used, include any information that conflicted, conflicts or will conflict with the information
contained in the Registration Statement or the Prospectus, including any incorporated document deemed to be a part thereof that has not
been superseded or modified. The foregoing sentence does not apply to statements in or omissions from any Issuer Free Writing Prospectus
based upon and in conformity with written information furnished to the Company by or on behalf of the Agent specifically for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)
<U>No Conflicts</U>. Neither the execution of this Agreement by the Company, nor the issuance, offering or sale of the Placement Shares,
nor the consummation of any of the transactions contemplated herein, nor the compliance by the Company with the terms and provisions
hereof will conflict with, or will result in a breach of, any of the terms and provisions of, or has constituted or will constitute a
default under, or has resulted in or will result in the creation or imposition of any lien, charge or encumbrance upon any property or
assets of the Company pursuant to the terms of any contract or other agreement to which the Company may be bound or to which any of the
property or assets of the Company is subject, except (i) such conflicts, breaches or defaults as may have been waived and (ii) such conflicts,
breaches and defaults that would not have a Material Adverse Effect; nor will such action result (x) in any violation of the provisions
of the organizational or governing documents of the Company, or (y) in any violation of the provisions of any statute or any order, rule
or regulation applicable to the Company or of any court or of any federal, state or other regulatory authority or other government body
having jurisdiction over the Company, other than in each case any such conflict, breach or violation that, individually or in the aggregate,
which would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)
<U>Sanctions</U>. (i) The Company represents that, neither it nor any Subsidiary (collectively, the &ldquo;<U>Entity</U>&rdquo;) nor,
any director, officer, employee, nor to the Entity&rsquo;s knowledge, any agent, affiliate or representative of the Entity, is a government,
individual, or entity (in this paragraph (uu), &ldquo;<U>Covered Person</U>&rdquo;) that is, or is owned or controlled by a Covered Person
that is:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
the subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control (&ldquo;<U>OFAC</U>&rdquo;),
the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively,
&ldquo;<U>Sanctions</U>&rdquo;), nor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
located, organized or resident in a country or territory that is the subject of Sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Entity represents and covenants that it will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other Covered Person:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
to fund or facilitate any activities or business of or with any Covered Person or in any country or territory that, at the time of such
funding or facilitation, is the subject of Sanctions; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
in any other manner that will result in a violation of Sanctions by any Covered Person (including any Covered Person participating in
the offering, whether as underwriter, advisor, investor or otherwise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Entity represents and covenants that, except as detailed in the Prospectus, for the past 5 years, it has not knowingly engaged in,
is not now knowingly engaged in, and will not knowingly engage in, any dealings or transactions with any Covered Person, or in any country
or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12pt; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)
<U>Stock Transfer Taxes</U>. On each Settlement Date, all stock transfer or other taxes (other than income taxes) which are required
to be paid in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid
or provided for by the Company and all laws imposing such taxes will be or will have been fully complied with in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(yy)
<U>IT Systems</U>. (i)(x)There has been no security breach or attack or other compromise of or relating to any of the Company&rsquo;s
and its subsidiaries&rsquo; information technology and computer systems, networks, hardware, software, data (including the data of their
respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of them), equipment or technology
(&ldquo;<U>IT Systems and Data</U>&rdquo;), and (y) the Company and its subsidiaries have not been notified of, and have no knowledge
of any event or condition that would reasonably be expected to result in any security breach, attack or compromise to their IT Systems
and Data, (ii) the Company and each of its subsidiaries have complied, and are presently in compliance with, all applicable laws, statutes
or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority and all industry guidelines,
standards, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection
of such IT Systems and Data from unauthorized use, access, misappropriation or modification and (iii) the Company and each of its subsidiaries
have implemented backup and disaster recovery technology consistent with industry standards and practice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
certificate signed by an officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or by the express
terms of this Agreement shall be deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters
set forth therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Covenants of the Company</U>. The Company covenants and agrees with Agent that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement Amendments</U>. After the date of this Agreement and during any period in which a Prospectus relating to any
Placement Shares is required to be delivered by Agent under the Securities Act (including in circumstances where such requirement may
be satisfied pursuant to Rule 172 under the Securities Act), (i) the Company will notify the Agent promptly of the time when any subsequent
amendment to the Registration Statement (other than documents incorporated by reference or amendments or supplements not related to any
Placement) has been filed with the Commission and/or has become effective or any subsequent supplement to the Prospectus has been filed
and of any request by the Commission for any amendment or supplement to the Registration Statement or Prospectus or for additional information
related to the transactions contemplated by this Agreement, (ii) the Company will prepare and file with the Commission, promptly upon
the Agent&rsquo;s reasonable request, any amendments or supplements to the Registration Statement or Prospectus that, in the Agent&rsquo;s
reasonable opinion, may be necessary or advisable in connection with the distribution of the Placement Shares by the Agent (provided,
however, that the failure of the Agent to make such request shall not relieve the Company of any obligation or liability hereunder, or
affect the Agent&rsquo;s right to rely on the representations and warranties made by the Company in this Agreement and provided, further,
that the only remedy the Agent shall have with respect to the failure to make such filing shall be to cease making sales under this Agreement
until such amendment or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement
or Prospectus, other than documents incorporated by reference, relating to the Placement Shares or a security convertible into the Placement
Shares unless a copy thereof has been submitted to Agent within a reasonable period of time before the filing and the Agent has not reasonably
objected thereto in writing within two (2) Business Days (provided, however, that (A) the failure of the Agent to make such objection
shall not relieve the Company of any obligation or liability hereunder, or affect the Agent&rsquo;s right to rely on the representations
and warranties made by the Company in this Agreement and (B) the Company has no obligation to provide the Agent any advance copy of such
filing or to provide Agent an opportunity to object to such filing if the filing does not name the Agent or does not relate to the transactions
contemplated by this Agreement; and provided, further, that the only remedy Agent shall have with respect to the failure by the Company
to obtain such consent shall be to cease making sales under this Agreement) and the Company will furnish to the Agent at the time of
filing thereof a copy of any document that upon filing is deemed to be incorporated by reference into the Registration Statement or Prospectus,
except for those documents available via EDGAR; and (iv) the Company will cause each amendment or supplement to the Prospectus to be
filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b) of the Securities Act or, in the case of any
document to be incorporated therein by reference, to be filed with the Commission as required pursuant to the Exchange Act, within the
time period prescribed (the determination to file or not file any amendment or supplement with the Commission under this Section 7(a),
based on the Company&rsquo;s reasonable opinion or reasonable objections, shall be made exclusively by the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Notice of Commission Stop Orders</U>. The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof,
of the issuance or threatened issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement,
of the suspension of the qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening
of any proceeding for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop
order or to obtain its withdrawal if such a stop order should be issued. The Company will advise the Agent promptly after it receives
any request by the Commission for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or any
Issuer Free Writing Prospectus or for additional information related to the offering of the Placement Shares or for additional information
related to the Registration Statement, the Prospectus or any Issuer Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Delivery of Prospectus; Subsequent Changes</U>. During any period in which a Prospectus relating to the Placement Shares is required
to be delivered by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares, (including in circumstances
where such requirement may be satisfied pursuant to Rule 172 under the Securities Act), the Company will use its commercially reasonable
efforts to comply with all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before
their respective due dates (taking into account any extensions available under the Exchange Act) all reports and any definitive proxy
or information statements required to be filed by the Company with the Commission pursuant to Sections 13(a), 13(c), 14, 15(d) or any
other provision of or under the Exchange Act. If the Company has omitted any information from the Registration Statement pursuant to
Rule 430B under the Securities Act, it will use commercially reasonable efforts to comply with the provisions of and make all requisite
filings with the Commission pursuant to said Rule 430B and to notify the Agent promptly of all such filings. If during such period any
event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading,
or if during such period it is necessary to amend or supplement the Registration Statement or Prospectus to comply with the Securities
Act, the Company will promptly notify Agent to suspend the offering of Placement Shares during such period and the Company will promptly
amend or supplement the Registration Statement or Prospectus (at the expense of the Company) so as to correct such statement or omission
or effect such compliance; provided, however, that the Company may delay the filing of any amendment or supplement, if in the judgment
of the Company, it is in the best interests of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Listing of Placement Shares</U>. During any period in which the Prospectus relating to the Placement Shares is required to be delivered
by the Agent under the Securities Act with respect to the offer and sale of the Placement Shares, the Company will use commercially reasonable
efforts to cause the Placement Shares to be listed on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Delivery of Registration Statement and Prospectus</U>. The Company will furnish to the Agent and its counsel (at the reasonable expense
of the Company) copies of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and
all amendments and supplements to the Registration Statement or Prospectus that are filed with the Commission during any period in which
a Prospectus relating to the Placement Shares is required to be delivered under the Securities Act (including all documents filed with
the Commission during such period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable
and in such quantities as the Agent may from time to time reasonably request and, at Agent&rsquo;s reasonable request, will also furnish
copies of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; provided, however, that the Company
shall not be required to furnish any document (other than the Prospectus) to the Agent or its counsel to the extent such document is
available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Earnings Statement</U>. The Company will make generally available to its security holders as soon as practicable, but in any event
not later than 15 months after the end of the Company&rsquo;s current fiscal quarter, an earnings statement covering a 12-month period
that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 under the Securities Act, provided that the Company
will be deemed to have furnished such statements to its security holders to the extent they are filed with the Commission on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Use of Proceeds</U>. The Company will use the Net Proceeds as described in the Prospectus in the section entitled &ldquo;Use of Proceeds.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Notice of Other Sales</U>. Without prior written notice to Agent, the Company will not, (A) directly or indirectly, offer to sell,
sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant
to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common
Stock during the period beginning on the date on which any Placement Notice is delivered to Agent hereunder and ending on the second
(2<SUP>nd</SUP>) Trading Day immediately following the final Settlement Date with respect to Placement Shares sold pursuant to such Placement
Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares covered by a Placement
Notice, the date of such suspension or termination); and (B) directly or indirectly in any other &ldquo;at the market&rdquo; or continuous
equity transaction offer to sell, sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than
the Placement Shares offered pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or
any rights to purchase or acquire, Common Stock prior to the termination of this Agreement; provided, however, that such restrictions
will not apply in connection with the Company&rsquo;s issuance, grant or sale of (i) Common Stock, restricted stock units, options to
purchase Common Stock or Common Stock issuable upon the exercise of options, or the vesting of any of the foregoing, pursuant to any
stock option, stock incentive or benefits plan, stock ownership plan or dividend reinvestment plan (but not Common Stock subject to a
waiver to exceed plan limits in its dividend reinvestment plan) of the Company whether now in effect or hereafter implemented, (ii) Common
Stock issuable upon conversion of securities or the exercise of warrants, options, convertible notes or other rights in effect or outstanding,
and disclosed in filings by the Company available on EDGAR or otherwise in writing to the Agent and (iii) Common Stock or securities
convertible into or exchangeable for shares of Common Stock issued in privately negotiated transactions to vendors, customers or other
commercial or strategic partners or potential commercial or strategic partners, as consideration for mergers, acquisitions, other business
combinations or strategic alliances occurring after the date of this Agreement which are not issued for capital raising purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>Change of Circumstances</U>. The Company will, at any time during the pendency of a Placement Notice advise the Agent promptly after
it shall have received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect
any opinion, certificate, letter or other document required to be provided to the Agent pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Due Diligence Cooperation</U>. The Company will cooperate with any reasonable due diligence review conducted by the Agent or its representatives
in connection with the transactions contemplated hereby, including, without limitation, providing information and making available documents
and senior corporate officers, during regular business hours and at the Company&rsquo;s principal offices, as the Agent may reasonably
request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Required Filings Relating to Placement of Placement Shares</U>. The Company agrees that on such dates as the Securities Act shall
require with respect to the Placement Shares, the Company will (i) file a prospectus supplement with the Commission under the applicable
paragraph of Rule 424(b) under the Securities Act (each and every filing under Rule 424(b), a &ldquo;<U>Filing Date</U>&rdquo;), which
prospectus supplement will set forth, within the relevant period, the amount of Placement Shares sold through the Agent, the Net Proceeds
to the Company and the compensation payable by the Company to the Agent with respect to such Placement Shares, and (ii) deliver such
number of copies of each such prospectus supplement to each exchange or market on which such sales were effected as may be required by
the rules or regulations of such exchange or market; provided that, if permitted by applicable law, the Company may satisfy the foregoing
requirement by providing the above information in its Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Representation Dates; Certificate</U>. On or prior to the date of the first Placement Notice delivered by the Company to the Agent
(such date, the &ldquo;<U>First Placement Date</U>&rdquo;) and each time the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
amends or supplements (other than a prospectus supplement relating solely to an offering of securities other than the Placement Shares)
the Registration Statement or the Prospectus relating to the Placement Shares by means of a post-effective amendment, sticker, or supplement
but not by means of incorporation of documents by reference into the Registration Statement or the Prospectus relating to the Placement
Shares;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
files an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A containing amended financial information or a material
amendment to the previously filed Form 10-K);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
files a quarterly report on Form 10-Q under the Exchange Act; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
files a current report on Form 8-K containing amended financial information (other than information &ldquo;furnished&rdquo; pursuant
to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of certain
properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(each
date of filing of one or more of the documents referred to in clauses (i) through (iv) shall be a &ldquo;<U>Representation Date.</U>&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Company shall furnish the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information contained
in such Form 8-K is material) with a certificate dated the Representation Date, in the form attached hereto as Exhibit 7(l). The requirement
to provide a certificate under this Section 7(l) shall be waived for any Representation Date occurring at a time at which no Placement
Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder
(which for such calendar quarter shall be considered a Representation Date) and the next occurring Representation Date; provided, however,
that such waiver shall not apply for any Representation Date on which the Company files its annual report on Form 10-K. Notwithstanding
the foregoing, if the Company subsequently decides to sell Placement Shares following a Representation Date when the Company relied on
such waiver and did not provide the Agent with a certificate under this Section 7(l), then before the Company delivers the Placement
Notice or the Agent sells any Placement Shares, the Company shall provide the Agent with a certificate, in the form attached hereto as
Exhibit 7(l), dated the date of the Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>Legal Opinion and Negative Assurance Letter</U>. (1) On or before the First Placement Date, the Company shall cause to be furnished
to the Agent a written opinion and negative assurance letter of Certilman Balin Adler &amp; Hyman, LLP (&ldquo;<U>Company Counsel</U>&rdquo;),
or other counsel reasonably satisfactory to the Agent, each in form and substance reasonably satisfactory to Agent and its counsel; and
(2) within five (5) Trading Days of each Representation Date with respect to which the Company is obligated to deliver a certificate
in the form attached hereto as Exhibit 7(l) for which no waiver is applicable, the Company shall cause to be furnished to the Agent a
negative assurance letter of Company Counsel, or other counsel reasonably satisfactory to the Agent, in form and substance reasonably
satisfactory to Agent and its counsel; <I>provided</I>, <I>however</I>, the Company shall not be required to furnish any such letter
if the Company does not intend to deliver a Placement Notice in such calendar quarter until such time as the Company delivers its next
Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>Comfort Letter</U>. (1) On or before the First Placement Date and (2) within five (5) Trading Days of each Representation Date, other
than pursuant to Section 7(l)(iii), with respect to which the Company is obligated to deliver a certificate in the form attached hereto
as Exhibit 7(l) for which no waiver is applicable, the Company shall cause its independent accountants to furnish the Agent letters (the
&ldquo;<U>Comfort Letters</U>&rdquo;), dated the date the Comfort Letter is delivered, which shall meet the requirements set forth in
this Section 7(n). The Comfort Letter from the Company&rsquo;s independent accountants shall be in a form and substance reasonably satisfactory
to the Agent, (i) confirming that they are an independent public accounting firm within the meaning of the Securities Act and the Public
Company Account Oversight Board, (ii) stating, as of such date, the conclusions and findings of such firm with respect to the financial
information and other matters ordinarily covered by accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters in connection with
registered public offerings (the first such letter, the &ldquo;<U>Initial Comfort Letter</U>&rdquo;) and (iii) updating the Initial Comfort
Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as
necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
<U>Market Activities</U>. The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes
or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone any compensation
for soliciting purchases of the Placement Shares other than the Agent; provided, however, that the Company may bid for and purchase shares
of its Common Stock in accordance with Rule 10b-18 under the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
<U>Investment Company Act</U>. The Company will conduct its affairs in such a manner so as to reasonably ensure that neither it nor the
Subsidiaries will be or become, at any time prior to the termination of this Agreement, an &ldquo;investment company,&rdquo; as such
term is defined in the Investment Company Act, assuming no change in the Commission&rsquo;s current interpretation as to entities that
are not considered an investment company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
<U>No Offer to Sell</U>. Other than the Prospectus and the Issuer Free Writing Prospectus approved in advance by the Company and the
Agent in its capacity as agent hereunder, neither the Agent nor the Company (including its agents and representatives, other than the
Agent in its capacity as such) will make, use, prepare, authorize, approve or refer to any written communication (as defined in Rule
405 under the Securities Act), required to be filed with the Commission, that constitutes an offer to sell or solicitation of an offer
to buy Placement Shares hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
<U>Blue Sky and Other Qualifications</U><I>. </I>The Company will use its commercially reasonable efforts, in cooperation with the Agent,
to qualify the Placement Shares for offering and sale, or to obtain an exemption for the Placement Shares to be offered and sold, under
the applicable securities laws of such states and other jurisdictions (domestic or foreign) as the Agent may designate and to maintain
such qualifications and exemptions in effect for so long as required for the distribution of the Placement Shares (but in no event for
less than one year from the date of this Agreement); <I>provided</I>, <I>however</I>, that the Company shall not be obligated to file
any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities in any jurisdiction in
which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise
so subject. In each jurisdiction in which the Placement Shares have been so qualified or exempt, the Company will file such statements
and reports as may be required by the laws of such jurisdiction to continue such qualification or exemption, as the case may be, in effect
for so long as required for the distribution of the Placement Shares (but in no event for less than one year from the date of this Agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
<U>Sarbanes-Oxley Act</U>. The Company will maintain and keep accurate books and records reflecting its assets and maintain internal
accounting controls in a manner designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted accounting principles and including those policies
and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions
and dispositions of the assets of the Company, (ii) provide reasonable assurance that transactions are recorded as necessary to permit
the preparation of the Company&rsquo;s financial statements in accordance with generally accepted accounting principles, (iii) that receipts
and expenditures of the Company are being made only in accordance with management&rsquo;s and the Company&rsquo;s directors&rsquo; authorization,
and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the
Company&rsquo;s assets that could have a material effect on its financial statements. The Company will maintain such controls and other
procedures, including, without limitation, those required by Sections 302 and 906 of the Sarbanes-Oxley Act, and the applicable regulations
thereunder that are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms, including, without limitation, controls and procedures designed to ensure that information required to be disclosed by the
Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&rsquo;s management,
including its principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to
allow timely decisions regarding required disclosure and to ensure that material information relating to the Company is made known to
it by others within the organization, particularly during the period in which such periodic reports are being prepared.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Payment of Expenses</U>. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including
(i) the preparation, filing, including any fees required by the Commission, and printing of the Registration Statement (including financial
statements and exhibits) as originally filed and of each amendment and supplement thereto, in such number as the Agent shall reasonably
deem necessary, (ii) the printing and delivery to the Agent of this Agreement and such other documents as may be required in connection
with the offering, purchase, sale, issuance or delivery of the Placement Shares, (iii) the fees and disbursements of the counsel, accountants
and other advisors to the Company, (iv) the reasonable and documented out-of-pocket expenses of Agent, including reasonable and documented
fees and disbursements of counsel to the Agent incurred in connection with (a) entering into the transactions contemplated by this Agreement
in an amount not to exceed $50,000 in the aggregate, and (b) ongoing diligence arising from the transactions contemplated by this Agreement
in an amount not to exceed $10,000 in the aggregate per calendar year; (v) the printing and delivery to the Agent of copies of any Permitted
Issuer Free Writing Prospectus (defined below) and the Prospectus and any amendments or supplements thereto in such number as the Agent
shall deem reasonably necessary, (vi) the preparation, printing and delivery to the Agent of copies of the blue sky survey, (vii) the
documented fees and expenses of the transfer agent and registrar for the Common Stock, (viii) the reasonable and documented fees and
expenses incident to any review by FINRA of the terms of the sale of the Placement Shares, including fees and expenses of counsel to
the Agent (subject to the aggregate maximum amount set forth above), and (ix) the documented fees and expenses incurred in connection
with the listing of the Placement Shares on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<U>Conditions to the Agent&rsquo;s Obligations</U>. The obligations of the Agent hereunder with respect to a Placement will be subject
to the continuing accuracy and completeness of the representations and warranties made by the Company herein, to the due performance
by the Company of its obligations hereunder, to the completion by the Agent of a due diligence review satisfactory to it in its reasonable
judgment, and to the continuing reasonable satisfaction (or waiver by the Agent in its sole discretion) of the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Registration Statement Effective</U>. The Registration Statement shall have become effective and shall be available for the sale of
all Placement Shares contemplated to be issued by any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>No Material Notices</U>. None of the following events shall have occurred and be continuing: (i) receipt by the Company of any request
for additional information from the Commission or any other federal or state governmental authority during the period of effectiveness
of the Registration Statement, the response to which would require any post-effective amendments or supplements to the Registration Statement
or the Prospectus; (ii) the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of the Registration Statement or the initiation of any proceedings for that purpose; (iii) receipt by the Company of
any notification with respect to the suspension of the qualification or exemption from qualification of any of the Placement Shares for
sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; or (iv) the occurrence of any event that
makes any statement of material fact made in the Registration Statement or the Prospectus or any material document incorporated or deemed
to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration
Statement, the Prospectus or Incorporated Documents so that, in the case of the Registration Statement, it will not contain any materially
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein not misleading and, that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>No Misstatement or Material Omission</U>. The Agent shall not have advised the Company that the Registration Statement or Prospectus,
or any amendment or supplement thereto, contains an untrue statement of fact that in the Agent&rsquo;s reasonable opinion, in consultation
with outside counsel, is material, or omits to state a fact that in the Agent&rsquo;s reasonable opinion is material and is required
to be stated therein or is necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Material Changes</U>. Except as contemplated in the Prospectus, or disclosed in the Company&rsquo;s reports filed with the Commission,
there shall not have been any Material Adverse Effect, or any development that would reasonably be expected to cause a Material Adverse
Effect, or a downgrading in or withdrawal of the rating assigned to any of the Company&rsquo;s securities (other than asset backed securities)
by any rating organization or a public announcement by any rating organization that it has under surveillance or review its rating of
any of the Company&rsquo;s securities (other than asset backed securities), the effect of which, in the case of any such action by a
rating organization described above, in the reasonable judgment of the Agent (without relieving the Company of any obligation or liability
it may otherwise have), is so material as to make it impracticable or inadvisable to proceed with the offering of the Placement Shares
on the terms and in the manner contemplated in the Prospectus..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Legal Opinion</U>. The Agent shall have received the opinion and the negative assurance letter of Company Counsel required to be delivered
pursuant to Section 7(m) on or before the date on which such delivery of such opinion and letter, as applicable, is required pursuant
to Section 7(m).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Comfort Letter</U>. The Agent shall have received the Comfort Letter required to be delivered pursuant to Section 7(n) on or before
the date on which such delivery of such Comfort Letter is required pursuant to Section 7(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
<U>Representation Certificate</U>. The Agent shall have received the certificate required to be delivered pursuant to Section 7(l) on
or before the date on which delivery of such certificate is required pursuant to Section 7(l).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
<U>Secretary&rsquo;s Certificate</U>. On or prior to the first Representation Date, the Agent shall have received a certificate, signed
on behalf of the Company by its corporate Secretary, in form and substance satisfactory to the Agent and its counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
<U>No Suspension</U>. Trading in the Common Stock shall not have been suspended on the Exchange, and the Common Stock shall not have
been delisted from the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
<U>Other Materials</U>. On each date on which the Company is required to deliver a certificate pursuant to Section 7(l), the Company
shall have furnished to the Agent such appropriate further information, certificates and documents as the Agent may reasonably request.
All such opinions, certificates, letters and other documents will be in compliance with the provisions hereof. The Company will furnish
the Agent with such conformed copies of such opinions, certificates, letters and other documents as the Agent shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
<U>Securities Act Filings Made</U>. All filings with the Commission required by Rule 424 under the Securities Act with respect to the
Placement Shares to have been filed prior to the issuance of any Placement Notice hereunder shall have been made within the applicable
time period prescribed for such filing by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
<U>Approval for Listing</U>. The Placement Shares shall either have been approved for listing on the Exchange, subject only to notice
of issuance, or the Company shall have filed an application for listing of the Placement Shares on the Exchange at, or prior to, the
issuance of any Placement Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
<U>FINRA</U>. FINRA shall have raised no objection to the terms of this offering and the amount of compensation allowable or payable
to the Agent as described in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
<U>No Termination Event</U>. There shall not have occurred any event that would permit the Agent to terminate this Agreement pursuant
to Section 12(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<U>Indemnification and Contribution</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Company Indemnification</U>. The Company agrees to indemnify and hold harmless the Agent, its partners, members, directors, officers,
employees and agents and each person, if any, who controls the Agent within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, arising out of or based upon
any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto),
or the omission or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein
not misleading, or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer
Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
against any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate
amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided
that (subject to Section 10(d) below) any such settlement is effected with the written consent of the Company, which consent shall not
unreasonably be delayed or withheld; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
against any and all expense whatsoever, as incurred (including the reasonable and documented fees and disbursements of counsel), reasonably
incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency
or body, commenced or threatened, or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue
statement or omission, of the Company to the extent that any such expense is not paid under (i) or (ii) above,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>provided</U>,
<U>however</U>, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with written
information furnished to the Company by or on behalf of the Agent expressly for use in the Registration Statement (or any amendment thereto),
or in any related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Agent Indemnification</U>. Agent agrees to indemnify and hold harmless the Company and its directors and each officer of the Company
who signed the Registration Statement, and each person, if any, who (i) controls the Company within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act or (ii) is controlled by or is under common control with the Company against any and
all loss, liability, claim, damage and expense described in the indemnity contained in Section 10(a), as incurred, but only with respect
to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendments thereto)
or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with information relating to the Agent
and furnished to the Company in writing by or on behalf of the Agent expressly for use therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Procedure</U>. Any party that proposes to assert the right to be indemnified under this Section 10 will, promptly after receipt of
notice of commencement of any action against such party in respect of which a claim is to be made against an indemnifying party or parties
under this Section 10, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served,
but the omission so to notify such indemnifying party will not relieve the indemnifying party from (i) any liability that it may have
to any indemnified party otherwise than under this Section 10 and (ii) any liability that it may have to any indemnified party under
the foregoing provision of this Section 10 unless, and only to the extent that, such omission results in the forfeiture of substantive
rights or defenses by the indemnifying party. If any such action is brought against any indemnified party and it notifies the indemnifying
party of its commencement, the indemnifying party will be entitled to participate in and, to the extent that it elects by delivering
written notice to the indemnified party promptly after receiving notice of the commencement of the action from the indemnified party,
jointly with any other indemnifying party similarly notified, to assume the defense of the action, with counsel reasonably satisfactory
to the indemnified party, and after notice from the indemnifying party to the indemnified party of its election to assume the defense,
the indemnifying party will not be liable to the indemnified party for any legal or other expenses except as provided below and except
for the reasonable and documented costs of investigation subsequently incurred by the indemnified party in connection with the defense.
The indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such
counsel will be at the expense of such indemnified party unless (1) the employment of counsel by the indemnified party has been authorized
in writing by the indemnifying party, (2) the indemnified party has reasonably concluded (based on advice of counsel) that there may
be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying
party, (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified party
and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on behalf
of the indemnified party) or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action within
a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable and documented fees,
disbursements and other charges of counsel will be at the expense of the indemnifying party or parties. It is understood that the indemnifying
party or parties shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable
fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction at any one time for all
such indemnified party or parties. All such fees, disbursements and other charges will be reimbursed by the indemnifying party promptly
after the indemnifying party receives a written invoice related to fees, disbursements and other reasonable charges in detail. An indemnifying
party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No indemnifying
party shall, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of any judgment
in any pending or threatened claim, action or proceeding relating to the matters contemplated by this Section 10 (whether or not any
indemnified party is a party thereto), unless such settlement, compromise or consent (1) includes an unconditional release of each indemnified
party from all liability arising out of such litigation, investigation, proceeding or claim and (2) does not include a statement as to
or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Contribution</U>. In order to provide for just and equitable contribution in circumstances in which the indemnification provided for
in the foregoing paragraphs of this Section 10 is applicable in accordance with its terms but for any reason is held to be unavailable
from the Company or the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses and damages
(including any investigative, legal and other expenses reasonably incurred and documented in connection with, and any amount paid in
settlement of, any action, suit or proceeding or any claim asserted, but after deducting any contribution received by the Company from
persons other than the Agent, such as persons who control the Company within the meaning of the Securities Act, officers of the Company
who signed the Registration Statement and directors of the Company, who also may be liable for contribution) to which the Company and
the Agent may be subject in such proportion as shall be appropriate to reflect the relative benefits received by the Company on the one
hand and the Agent on the other hand. The relative benefits received by the Company on the one hand and the Agent on the other hand shall
be deemed to be in the same proportion as the total net proceeds from the sale of the Placement Shares (before deducting expenses) received
by the Company bear to the total compensation received by the Agent (before deducting expenses) from the sale of Placement Shares on
behalf of the Company. If, but only if, the allocation provided by the foregoing sentence is not permitted by applicable law, the allocation
of contribution shall be made in such proportion as is appropriate to reflect not only the relative benefits referred to in the foregoing
sentence but also the relative fault of the Company, on the one hand, and the Agent, on the other hand, with respect to the statements
or omission that resulted in such loss, claim, liability, expense or damage, or action in respect thereof, as well as any other relevant
equitable considerations with respect to such offering. Such relative fault shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to
information supplied by the Company or the Agent, the intent of the parties and their relative knowledge, access to information and opportunity
to correct or prevent such statement or omission. The Company and the Agent agree that it would not be just and equitable if contributions
pursuant to this Section 10(d) were to be determined by pro rata allocation or by any other method of allocation that does not take into
account the equitable considerations referred to herein. The amount paid or payable by an indemnified party as a result of the loss,
claim, liability, expense, or damage, or action in respect thereof, referred to above in this Section 10(d) shall be deemed to include,
for the purpose of this Section 10(d), any legal or other expenses reasonably incurred by such indemnified party in connection with investigating
or defending any such action or claim to the extent consistent with Section 10(c) hereof. Notwithstanding the foregoing provisions of
this Section 10(d), the Agent shall not be required to contribute any amount in excess of the commissions received by it under this Agreement
and no person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes of this Section 10(d), any person
who controls a party to this Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or
agents of the Agent, will have the same rights to contribution as that party, and each director of the Company and each officer of the
Company who signed the Registration Statement will have the same rights to contribution as the Company, subject in each case to the provisions
hereof. Any party entitled to contribution, promptly after receipt of notice of commencement of any action against such party in respect
of which a claim for contribution may be made under this Section 10(d), will notify any such party or parties from whom contribution
may be sought, but the omission to so notify will not relieve that party or parties from whom contribution may be sought from any other
obligation it or they may have under this Section 10(d) except to the extent that the failure to so notify such other party materially
prejudiced the substantive rights or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant
to the last sentence of Section 10(c) hereof, no party will be liable for contribution with respect to any action or claim settled without
its written consent if such consent is required pursuant to Section 10(c) hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<U>Additional Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Representations and Covenants of the Agent</U>. The Agent represents and warrants that it is duly registered as a broker-dealer under
FINRA, the Exchange Act and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold,
except such states in which the Agent is exempt from registration or such registration is not otherwise required. The Agent shall continue,
for the term of this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act and the applicable statutes and
regulations of each state in which the Placement Shares will be offered and sold, except such states in which the Agent is exempt from
registration or such registration is not otherwise required, during the term of this Agreement. The Agent shall comply with all applicable
law and regulations in connection with the transactions contemplated by this Agreement, including the issuance and sale through the Agent
of the Placement Shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Representations and Agreements to Survive Delivery</U>. The indemnity and contribution agreements contained in Section 10 of this
Agreement and all representations and warranties of the Company herein or in certificates delivered pursuant hereto shall survive, as
of their respective dates, regardless of (i) any investigation made by or on behalf of the Agent, any controlling persons, or the Company
(or any of their respective officers, directors or controlling persons), (ii) delivery and acceptance of the Placement Shares and payment
therefor or (iii) any termination of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<U>Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Agent may terminate this Agreement, by written notice to the Company, as hereinafter specified at any time (1) if there has been,
since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any Material Adverse
Effect, or any development that would reasonably be expected to result in a Material Adverse Effect has occurred, which in the reasonable
judgment of the Agent, is material and adverse and makes it impractical or inadvisable to market the Placement Shares, (2) if there has
occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak
of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective change in national
or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment
of the Agent, impracticable or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares,
(3) if trading in the Common Stock has been suspended or limited by the Commission or the Exchange, or if trading generally on the Exchange
has been suspended or limited, or minimum prices for trading have been fixed on the Exchange, (4) if any suspension of trading of any
securities of the Company on any exchange or in the over-the-counter market shall have occurred and be continuing, (5) if a major disruption
of securities settlements or clearance services in the United States shall have occurred and be continuing, or (6) if a banking moratorium
has been declared by either U.S. Federal or New York authorities. Any such termination shall be without liability of any party to any
other party except that the provisions of Section 8 (Expenses), Section 10 (Indemnification), Section 11 (Survival of Representations),
Section 17 (Governing Law; Consent to Jurisdiction) and Section 18 (Waiver of Jury Trial) hereof shall remain in full force and effect
notwithstanding such termination. If the Agent elects to terminate this Agreement as provided in this Section 12(a), the Agent shall
provide the required written notice as specified in Section 13 (Notices).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Company shall have the right, by giving ten (10) days written notice as hereinafter specified to terminate this Agreement in its
sole discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other
party except that the provisions of Section 8, Section 10, Section 11, Section 17 and Section 18 hereof shall remain in full force and
effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Agent shall have the right, by giving ten (10) days written notice as hereinafter specified to terminate this Agreement in its sole
discretion at any time after the date of this Agreement. Any such termination shall be without liability of any party to any other party
except that the provisions of Section 8, Section 10, Section 11, Section 17 and Section 18 hereof shall remain in full force and effect
notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Unless earlier terminated pursuant to this Section 12, this Agreement shall automatically terminate upon the issuance and sale of all
of the Placement Shares through the Agent on the terms and subject to the conditions set forth herein; provided that the provisions of
Section 8, Section 10, Section 11, Section 17 and Section 18 hereof shall remain in full force and effect notwithstanding such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
This Agreement shall remain in full force and effect unless terminated pursuant to Sections 12(a), (b), (c), or (d) above or otherwise
by mutual agreement of the parties; provided, however, that any such termination by mutual agreement shall in all cases be deemed to
provide that Section 8, Section 10, Section 11, Section 17 and Section 18 shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Any termination of this Agreement shall be effective on the date specified in such notice of termination; provided, however, that such
termination shall not be effective until the close of business on the date of receipt of such notice by the Agent or the Company, as
the case may be; provided, further, any termination of this Agreement in accordance with the terms of Section 12(b) or (c) shall not
be effective until the date that is ten days after the date of such written notice. If such termination shall occur prior to the Settlement
Date for any sale of Placement Shares, such Placement Shares shall settle in accordance with the provisions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Subject to the additional limitations set forth in Section 8 of this Agreement, in the event of termination of this Agreement prior to
the sale of any Placement Shares, the Agent shall be entitled only to reimbursement of its out-of-pocket expenses actually incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<U>Notices</U>. All notices or other communications required or permitted to be given by any party to any other party pursuant to the
terms of this Agreement shall be in writing, unless otherwise specified, and if sent to the Agent, shall be delivered to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JonesTrading
    Institutional Services LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">900
    Island Park Drive, Suite 200</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel
    Island, SC 29492</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Burke Cook</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    burke@jonestrading.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Duane
    Morris, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1540
    Broadway</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">New
    York, NY 10036</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Dean M. Colucci</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email:
    DMColucci@duanemorris.com </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
    if to the Company, shall be delivered to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">BioRestorative Therapies,
    Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">40 Marcus Drive, Suite
    One</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Melville, NY 11747</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Attn: Lance Alstodt,
    Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email: <U>lalstodt@biorestorative.com</U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
    a copy to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certilman
    Balin Adler &amp; Hyman, LLP</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">90
    Merrick Avenue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">East
    Meadow, NY 11554</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
    Fred Skolnik, Esq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Email:
    <U>fskolnik@certilmanbalin.com</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose. Each such notice or other communication shall be deemed given (i) when delivered personally or by verifiable facsimile
transmission (with an original to follow) on or before 4:30 p.m., New York City time, on a Business Day (as defined below) or, if such
day is not a Business Day, on the next succeeding Business Day, (ii) on the next Business Day after timely delivery to a nationally-recognized
overnight courier and (iii) on the Business Day actually received if deposited in the U.S. mail (certified or registered mail, return
receipt requested, postage prepaid).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
electronic communication (&ldquo;<U>Electronic Notice</U>&rdquo;) shall be deemed written notice for purposes of this Section 13 if sent
to the electronic mail address specified by the receiving party under separate cover. Electronic Notice shall be deemed received at the
time the party sending Electronic Notice receives verification of receipt by the receiving party. Any party receiving Electronic Notice
may request and shall be entitled to receive the notice on paper, in a nonelectronic form (&ldquo;<U>Nonelectronic Notic</U>e&rdquo;)
which shall be sent to the requesting party within ten (10) days of receipt of the written request for Nonelectronic Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<U>Successors and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the Company and the Agent and their respective
successors and the affiliates, controlling persons, officers and directors referred to in Section 10 hereof. References to any of the
parties contained in this Agreement shall be deemed to include the successors and permitted assigns of such party. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assigns
any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.
Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party; provided,
however, that the Agent may assign its rights and obligations hereunder to an affiliate thereof without obtaining the Company&rsquo;s
consent, so long as such affiliate is a registered broker dealer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<U>Adjustments for Stock Splits</U>. The parties acknowledge and agree that all share-related numbers contained in this Agreement shall
be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<U>Entire Agreement; Amendment; Severability</U>. This Agreement (including all schedules and exhibits attached hereto and Placement
Notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements and undertakings,
both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor any term hereof
may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one or more of the
provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable as written by
a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is
valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or
unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the remainder
of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
<U>GOVERNING LAW AND TIME; WAIVER OF JURY TRIAL</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF
THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. EACH
PARTY HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.
<B><U>CONSENT TO JURISDICTION</U>. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS
SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION
CONTEMPLATED HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS
NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM
OR THAT THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND
CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN
RECEIPT REQUESTED) TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE
GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO
SERVE PROCESS IN ANY MANNER PERMITTED BY LAW.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.
<U>Use of Information</U>. The Agent may not use any information gained in connection with this Agreement and the transactions contemplated
by this Agreement, including due diligence, to advise any party with respect to transactions not expressly approved by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.
<U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Delivery of an executed Agreement by one party to the other may be made
by facsimile or other electronic transmission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.
<U>Effect of Headings</U>. The section and Exhibit headings herein are for convenience only and shall not affect the construction hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.
<U>Permitted Free Writing Prospectuses</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company represents, warrants and agrees that, unless it obtains the prior consent of the Agent (which consent shall not be unreasonably
withheld or delayed), and the Agent represents, warrants and agrees that, unless it obtains the prior consent of the Company, it has
not made and will not make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that
would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule 405, required to be filed with the Commission.
Any such free writing prospectus consented to by the Agent or by the Company, as the case may be (a &ldquo;<U>Permitted Free Writing
Prospectus</U>&rdquo;). The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing
Prospectus as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, and has complied and will comply with the requirements
of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely filing with the Commission where required, legending
and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.
<U>Absence of Fiduciary Relationship</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand,
and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether or not the Agent has advised or is advising the Company on other matters, and the Agent has no obligation to the Company with
respect to the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
the Agent has not provided any legal, accounting, regulatory or tax advice with respect to the transactions contemplated by this Agreement
and it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
it is aware that the Agent and its affiliates are engaged in a broad range of transactions which may involve interests that differ from
those of the Company and the Agent has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary,
advisory or agency relationship or otherwise; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
it waives, to the fullest extent permitted by law, any claims it may have against the Agent for breach of fiduciary duty or alleged breach
of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that the Agent shall not have any liability
(whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim or to any person asserting
a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company, other than in respect of the
Agent&rsquo;s obligations under this Agreement and to keep information provided by the Company to the Agent and the Agent&rsquo;s counsel
confidential to the extent not otherwise publicly-available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.
<U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the following terms have the respective meanings set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Applicable
Time</U>&rdquo; means (i) each Representation Date, (ii) the time of each sale of any Placement Shares pursuant to this Agreement, and
(iii) each Settlement Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; shall mean any day on which the Exchange and commercial banks in the City of New York are open for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Issuer
Free Writing Prospectus</U>&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, relating to the Placement
Shares that (1) is required to be filed with the Commission by the Company, (2) is a &ldquo;road show&rdquo; that is a &ldquo;written
communication&rdquo; within the meaning of Rule 433(d)(8)(i) whether or not required to be filed with the Commission, or (3) is exempt
from filing pursuant to Rule 433(d)(5)(i) because it contains a description of the Placement Shares or of the offering that does not
reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company&rsquo;s records pursuant to Rule 433(g) under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
172</U>,&rdquo; &ldquo;<U>Rule 405</U>,&rdquo; &ldquo;<U>Rule 415</U>,&rdquo; &ldquo;<U>Rule 424</U>,&rdquo; &ldquo;<U>Rule 424(b)</U>,&rdquo;
&ldquo;<U>Rule 430B</U>,&rdquo; and &ldquo;<U>Rule 433</U>&rdquo; refer to such rules under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company that may be identified on Exhibit 21.1 to the Company&rsquo;s Annual Report on Form 10-K for the
most recently ended fiscal year, and shall, where applicable, also include any direct or indirect subsidiary of the Company formed or
acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means any day on which shares of Common Stock are purchased and sold on the Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to financial statements and schedules and other information that is &ldquo;contained,&rdquo; &ldquo;included&rdquo;
or &ldquo;stated&rdquo; in the Registration Statement or the Prospectus (and all other references of like import) shall be deemed to
mean and include all such financial statements and schedules and other information that is incorporated by reference in the Registration
Statement or the Prospectus, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing
Prospectus (other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the Commission)
shall be deemed to include the copy thereof filed with the Commission pursuant to EDGAR; and all references in this Agreement to &ldquo;supplements&rdquo;
to the Prospectus shall include, without limitation, any supplements, &ldquo;wrappers&rdquo; or similar materials prepared in connection
with any offering, sale or private placement of any Placement Shares by the Agent outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page Follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the foregoing correctly sets forth the understanding between the Company and the Agent, please so indicate in the space provided below
for that purpose, whereupon this letter shall constitute a binding agreement between the Company and the Agent.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
truly yours,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ACCEPTED
    as of the date first-above written:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>JONESTRADING
    INSTITUTIONAL SERVICES LLC</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
Page to Capital on Demand&trade; Sales Agreement] </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM
OF PLACEMENT NOTICE</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIORESTORATIVE
    THERAPIES, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JONESTRADING
    INSTITUTIONAL SERVICES LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    ___________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Placement
    Notice</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms and subject to the conditions contained in the Capital on Demand<B>&trade;</B> Sales Agreement between BioRestorative Therapies,
Inc. (the &ldquo;<U>Company</U>&rdquo;) and JonesTrading Institutional Services LLC (&ldquo;<U>Agent</U>&rdquo;), dated April 14, 2023,
the Company hereby requests that the Agent sell up to ____________ of the Company&rsquo;s Common Stock, $0.0001 par value per share,
at a minimum market price of $_______ per share, during the time period beginning [month, day, time] and ending [month, day, time].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay to the Agent in cash, upon each sale of Placement Shares pursuant to this Agreement, an amount equal to 3.0% of the
gross proceeds from each sale of Placement Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SCHEDULE
3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notice
Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Company</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lance
    Alstodt</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lalstodt@biorestorative.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert
    Kristal</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">rkristal@biorestorative.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The
Agent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moe
    Cohen </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">moec@jonestrading.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bryan
    Turley </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bturley@jonestrading.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    D&rsquo;Agostini </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">johnd@jonestrading.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Gerety </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ryang@jonestrading.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Burke
    Cook </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">burke@jonestrading.com</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Loforte</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;rloforte@jonestrading.com</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
a copy to JTCM@jonestrading.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
7(l)</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
of Representation Date Certificate</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>____________________,
20__</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Representation Date Certificate (this &ldquo;<U>Certificate</U>&rdquo;) is executed and delivered in connection with Section 7(l) of
the Capital on Demand<B>&trade;</B> Sales Agreement (the &ldquo;<U>Agreement</U>&rdquo;), dated April 14, 2023, and entered into between
BioRestorative Therapies, Inc. (the &ldquo;<U>Company</U>&rdquo;) and JonesTrading Institutional Services LLC. All capitalized terms
used but not defined herein shall have the meanings given to such terms in the Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, a duly appointed and authorized officer of the Company, having made all necessary inquiries to establish the accuracy of
the statements below and having been authorized by the Company to execute this certificate, hereby certifies as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
As of the date of this Certificate, (i) the Registration Statement does not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein not misleading and (ii) neither
the Registration Statement nor the Prospectus contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading and (iii) no event has occurred as a result of which it is necessary to amend or supplement the Prospectus in order to
make the statements therein not untrue or misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Each of the representations and warranties of the Company contained in the Agreement (A) to the extent such representations and warranties
are subject to qualifications and exceptions contained therein relating to materiality or Material Adverse Effect, are true and correct
on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof, except for those representations
and warranties that speak solely as of a specific date and which were true and correct as of such date, and (B) to the extent such representations
and warranties are not subject to any qualifications or exceptions, are true and correct in all material respects as of the date hereof
as if made on and as of the date hereof with the same force and effect as if expressly made on and as of the date hereof except for those
representations and warranties that speak solely as of a specific date and which were so true and correct as of such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Each of the covenants required to be performed by the Company in the Agreement on or prior to the date of the Agreement, this Representation
Date, and each such other date as set forth in the Agreement, has been duly, timely and fully performed in all material respects and
each condition required to be complied with by the Company on or prior to the date of the Agreement, this Representation Date, and each
such other date as set forth in the Agreement has been duly, timely and fully complied with in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Subsequent to the date of the most recent financial statements in the Prospectus, there has been no Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
No stop order suspending the effectiveness of the Registration Statement or of any part thereof has been issued, and no proceedings for
that purpose have been instituted or are pending or threatened by any securities or other governmental authority (including, without
limitation, the Commission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
No order suspending the effectiveness of the Registration Statement or the qualification or registration of the Placement Shares under
the applicable securities or blue sky laws of any applicable jurisdiction are in effect and no proceeding for such purpose is pending
before, or threatened, to the Company&rsquo;s knowledge or in writing by, any applicable securities or other governmental authority (including,
without limitation, the Commission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned has executed this Representation Date Certificate as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BIORESTORATIVE
    THERAPIES, INC.</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FRED
S. SKOLNIK</B></FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PARTNER</FONT></P>



<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECT
DIAL 516.296.7048</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fskolnik@certilmanbalin.com</FONT></P>



<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
14, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 3.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioRestorative
Therapies, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40
Marcus Drive</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite
One</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melville,
New York 11747</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have acted as counsel to BioRestorative Therapies, Inc., a Nevada corporation (the &ldquo;Company&rdquo;), in connection with the Registration
Statement on Form S-3 (File No. 333-269631) (the &ldquo;Registration Statement&rdquo;) filed with the Securities and Exchange Commission
(the &ldquo;Commission&rdquo;) pursuant to the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the rules and
regulations thereunder (the &ldquo;Rules&rdquo;), which became effective on February 14, 2023. You have asked us to furnish our opinion
as to the legality of shares (the &ldquo;Shares&rdquo;) of common stock of the Company, par value $0.0001 per share (the &ldquo;Common
Stock&rdquo;), having an aggregate offering price of up to $3,700,000, which are registered under the Registration Statement and which
are subject to sale pursuant to the Capital on Demand&trade; Sales Agreement (the &ldquo;Sales Agreement&rdquo;), dated as of April 14,
2023, by and between the Company and JonesTrading Institutional Services LLC, as sales agent and/or principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the furnishing of this opinion, we have examined originals, or copies certified or otherwise identified to our satisfaction,
of the following documents:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.5in">1.</TD>
  <TD STYLE="text-align: justify">the Registration Statement;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">2.</TD>
  <TD STYLE="text-align: justify">the final prospectus supplement dated April 14, 2023 (the &ldquo;Final Prospectus&rdquo;); and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
  <TD STYLE="text-align: justify">3.</TD>
  <TD STYLE="text-align: justify">the Sales Agreement.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we have examined (i) such corporate records of the Company as we have considered appropriate, including a copy of the amended
and restated articles of incorporation and by-laws of the Company and copies of resolutions of the board of directors of the Company
relating to the issuance of the Shares, and (ii) such other certificates, agreements and documents as we deemed relevant and necessary
as a basis for the opinions expressed below. We have also relied upon the factual matters contained in the representations and warranties
of the Company made in the documents reviewed by us and upon certificates of public officials and the officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><IMG SRC="ex5-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex5-1_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
14, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our examination of the documents referred to above, we have assumed, without independent investigation, the genuineness of all signatures,
the legal capacity of all individuals who have executed any of the documents reviewed by us, the authenticity of all documents submitted
to us as originals, the conformity to the originals of all documents submitted to us as certified, photostatic, reproduced or conformed
copies of valid existing agreements or other documents, the authenticity of all such latter documents and that the statements regarding
matters of fact in the certificates, records, agreements, instruments and documents that we have examined are accurate and complete.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon the above, and subject to the stated assumptions, exceptions and qualifications, we are of the opinion that the Shares have been
duly authorized by all necessary corporate action on the part of the Company and, when issued, delivered and paid for as contemplated
in the Registration Statement and in accordance with the terms of the Sales Agreement, the Shares will be validly issued, fully paid
and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opinion expressed above is limited to the Nevada Revised Statutes. Our opinion is rendered only with respect to the laws, and the rules,
regulations and orders under those laws, that are currently in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use of this opinion as an exhibit to the Company&rsquo;s Current Report on Form 8-K filed by the Company with the
Commission on the date hereof, and to the use of our name under the heading &ldquo;Legal Matters&rdquo; contained in the base prospectus
included in the Registration Statement and in the Final Prospectus. In giving this consent, we do not thereby admit that we come within
the category of persons whose consent is required by the Securities Act or the Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTILMAN
    BALIN ADLER &amp; HYMAN, LLP</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Fred Skolnik</I>&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fred
    Skolnik, a member of the Firm</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><IMG SRC="ex5-1_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex5-1_001.jpg
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( IX# 2(  A$! Q$!_\0
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MX&\6Z=J/A#]GN\^&WQ@_:&>Q\60VTNM_"7XH:W=?"H7T^AZ!X?U.U\<6>D>
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MKX5^!_ 7Q]\&O,N%G6TT*"Q\4V,MV9DT6TT76[^WBCGNQ(W>?&/X=ZC\3?\
M@EI_P40^.WC31[_3O'O[7?P9^+?[0$.EZM9B#5_"_P +O"OPVEN?V:OAW=PJ
MSR:?J/A?X3>#_">K^*-%>7R+3XJ>+OB#<PJ\NI7"G]EM*^&7@+2/"+_#[3?
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MT[2KS5_B#INDRZ?JEU)J*S>$[_5?#_AFU?PLNGZ7'82]?K/[(NF:_9?&L/\
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MW=7_ .A.UO\ \&'A;_YH*/[=U?\ Z$[6_P#P8>%O_F@HHH /[=U?_H3M;_\
M!AX6_P#F@H_MW5_^A.UO_P &'A;_ .:"BB@ _MW5_P#H3M;_ /!AX6_^:"C^
MW=7_ .A.UO\ \&'A;_YH*** #^W=7_Z$[6__  8>%O\ YH*/[=U?_H3M;_\
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M'A;_ .:"BB@ _MW5_P#H3M;_ /!AX6_^:"C^W=7_ .A.UO\ \&'A;_YH***
M#^W=7_Z$[6__  8>%O\ YH*/[=U?_H3M;_\ !AX6_P#F@HHH /[=U?\ Z$[6
M_P#P8>%O_F@H_MW5_P#H3M;_ /!AX6_^:"BB@ _MW5_^A.UO_P &'A;_ .:"
MC^W=7_Z$[6__  8>%O\ YH*** #^W=7_ .A.UO\ \&'A;_YH*/[=U?\ Z$[6
M_P#P8>%O_F@HHH /[=U?_H3M;_\ !AX6_P#F@H_MW5_^A.UO_P &'A;_ .:"
MBB@ _MW5_P#H3M;_ /!AX6_^:"C^W=7_ .A.UO\ \&'A;_YH*** #^W=7_Z$
M[6__  8>%O\ YH*/[=U?_H3M;_\ !AX6_P#F@HHH /[=U?\ Z$[6_P#P8>%O
M_F@H_MW5_P#H3M;_ /!AX6_^:"BB@ _MW5_^A.UO_P &'A;_ .:"C^W=7_Z$
M[6__  8>%O\ YH*** #^W=7_ .A.UO\ \&'A;_YH*/[=U?\ Z$[6_P#P8>%O
M_F@HHH /[=U?_H3M;_\ !AX6_P#F@H_MW5_^A.UO_P &'A;_ .:"BB@ _MW5
M_P#H3M;_ /!AX6_^:"C^W=7_ .A.UO\ \&'A;_YH*** #^W=7_Z$[6__  8>
M%O\ YH*/[=U?_H3M;_\ !AX6_P#F@HHH /[=U?\ Z$[6_P#P8>%O_F@H_MW5
M_P#H3M;_ /!AX6_^:"BB@ _MW5_^A.UO_P &'A;_ .:"C^W=7_Z$[6__  8>
M%O\ YH*** #^W=7_ .A.UO\ \&'A;_YH*/[=U?\ Z$[6_P#P8>%O_F@HHH 0
MZ[JX!)\'ZW@ G_D(>%1T]SXA _,@5MZ?=RWEOYTUE/I\F]U-M<2VDT@4'Y'\
4RQN;NW*R*0P"3,5Y# $444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex5-1_002.jpg
<TEXT>
begin 644 ex5-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  D IX# 2(  A$! Q$!_\0
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M6U+PU;:%H^D7US;3=;XI^!^J^/\ X<Z1X-\<_%?Q9=7VB_&33/BS!XKTK2/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_003.jpg
<TEXT>
begin 644 ex5-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !  -<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^OG_AT[_P
M2R_Z1I_L ?\ B&_[.O\ \[FC_AT[_P $LO\ I&G^P!_XAO\ LZ__ #N*^_69
M5#,S*JJ"S,2 %4#)+$G   )). !SVS7GR?%GX72:LV@Q_$CP&^MH2K:,GB_P
M^^J*5'*MIZ7[78(')7RLCKTJHTZE2[ITZM115Y.G2J5%%;WDZ=.IRJR;O+E5
MKNYE5K4J7+[6K2I<SM'VM6E3YGVC[2I3YGY1YGY'R'_PZ=_X)9?](T_V /\
MQ#?]G7_YW-'_  Z=_P""67_2-/\ 8 _\0W_9U_\ G<U]^HZ.JNCJZ.JNCJP9
M61AE75@2&5ARK D$<@D4NX=,C_/KZ?C4FJUVU]#X!_X=._\ !++_ *1I_L ?
M^(;_ +.O_P [FC_AT[_P2R_Z1I_L ?\ B&_[.O\ \[FOO[(]1^=+0!\ ?\.G
M?^"67_2-/]@#_P 0W_9U_P#G<UA>(/\ @F#_ ,$EO"FF3ZSXB_X)T?\ !/;2
M--M\"6[O?V//V=(XR[#*0Q(/ARTD\\A&(K>WCEGD92J(QZ_H'K^NZ;X9T;5=
M?UBX6UTW2+.:^O)CR5@@4MM1,C?+(Q6*&,$-+*Z1KRPKX=\%:5J_[2_CV_\
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MZ>T<YS?J^>"OU]U61^)^J?\ !.O]D'PO&UQKG_!'?_@G+JME""TUSX=_9#^
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MWNV*V^J:?^R3^S1KUC,4YF\B6#X:VT4YB!WM!#</<A,.("I7/T#X:_X)A_\
M!);Q?H]IKWAW_@G)_P $^=3TN\4F&Y@_8X_9VR&0XE@GB?X<+-;W,+?)/;SQ
MQS1/PZ]"?N'XF>$+'QQX(\0^'[Z))&N-.N)["4J#)9ZK:Q//IU[ Q!:.2&Y1
M0Q0AI(7EA8E)&!^+/V1_%?\ 9OBCQ%X8O=2M;;3]5T9-9BM+N\MX#_:=A=VU
MFTMI%,Z-(\UK>".X\A6+"WA:3 C!%J52%:%)MU(U$^5J/OIQ6J:@G==6^72^
MK2)<*=3#U*R2I3HN/M%S?NW%NRDG.2Y7T2<M7IJ[&A_PZ=_X)9?](T_V /\
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M$IQH4HQHRJ2I3JXBI6K?C[H$7A+_ ((]?"'Q9I5OX(^)7Q$^"OQ&_:TM=/\
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M[FZE6:ZFT3P?\-+O0=,FNI4^2:::ST^&261?E9W9EP"!7I<29+D^18_$X?\
ML:HK\69ODF!C6S'&5,+7RG XG 488OVU"I*2S##UL2\%5IO$0C5IU5BJN!H3
MI1=3Q^&\]SS/<OHUWG%)*/"F59YCJE++L)3Q-'-\9A<RJ_5(T,12C3EEN(HX
M2.-A5C3G*G.D\+2QE6-:4:/YY_$K]O\ UKXV_!WX+>+_  7^R]\>K#X5?'.?
MPIXET7QUJNI?!U;,^$-=OK*RTG7-8T'0_B;KGBVQTJTU#5+"_P!8CGT!+FSM
MK?SC#)&DYB^B?V!OVEK+XR?#/XP:5X)^$OC/1]5^!/Q)\6_#'Q;'XCUCP?;)
MXL^*>B+;ZEK6F>&;S3M8OXWTFVT[4=%BL_$.L+IMM=><L446+>5D^%/V6=__
M  P3_P $].?E'[*'@?9C&=YW++@A@,A?+!Y)]3GK[U_P1Q97T#]NYDPJG_@H
M#\9E (P1L\)?#M"!P>=RG!/!&6R<FO.S#+<EC4X[AALJCAJO"^883 X&LLPS
M"NZU*OQ/F675)XBEB)\CJ2P>"ITI.E[.'M)2JJ,9\L8_187,,ZC0X"=7-98B
MCQ1A<=C<?2E@,OHNE5H\-8+,:<,/5H04U3CC,5*JO:QG-PA"BY2I\Q]T_L??
MM6:+^V+\*IOB_P"%O 'B_P !^%6\6>*O"&FVWC>Y\-OK6I:IX'\1:EX1\42"
MR\,ZSKMM9V=CXBTF^L+22XO5EOXXA>10);R1L_:Z1^T9\.=4_:/\8?LLI>W%
MM\4_"'PF\'?&>6QN%A%KJW@OQ?XC\2>%_M6DR)*\TL^@:KH%LFO1S0Q+;Q^(
MM!DA><7,HA^$?^"*)S^PGHQQT^.W[46 1CD?M"_$3(.>5P0OTQT/2OAW]K%/
M%WP\_:W_ &E/^"C7@+3+[5=4_86^,'[/_@/XB6.ERR32>,?V5?$GP.\-W_Q_
M\)K8HQCNK[P;<_$>Q^)6GF0$:?<^'+BZ=6*J8^Y\+Y;B>+N+<BHNMA:&!>-P
M>1?O'5C_ &K+'9?@<FP^+K5G%SI8W%5JN#G6DX.G4QF&JM*G3FEY7^M.:83A
M/A'/*L:6+KYA]1Q6=I4%";RJ."Q^-SC$8:C2YHPJX+#4J>+ITXJ2G3PN(IJ\
MZB;_ *&_B!X[\,?#+P/XP^(OC/4H='\(^ _#&O>,?$^JW# 0Z=H/AO3;C5=5
MO'+,H(M[*WEE"9^=@J*26 /.?"GX@^$_CO\ "?X5_%_1+"9O#7Q'\&^#?BAX
M6M]7@MSJ&G6GBG0[3Q!HS74<3SPV^KV-M?B*?R)9!;W2S)'*P&X_$W[5.H:#
M^UP_PQ_99\(7]MXF^&GQ9^'MY^T#\9=4TNY;[#JGP%TJS#?#?PV;A(U?[-\9
MOB5=>'UACBD1]5\$^"?B'9E60MCP/]B/]I2'X2_\$5O@[\<)K:76-6^%_P"S
MS=^'-&TEHWN+OQ-\0?!>MZK\,/"/A6UA0B2>[\6^.K#2]!TRV3$D\VIVL48#
M.!7B0X>Y\@P^,@J\LYQ/$."RR.#<%&G2PF8X7&T\ ZG-)3AB<5F.78QVG&$:
M>%P]Y6;;7KU.*%2XAQ&$J2P\<FPW#V-S+ZXI.<ZV,RW$X*KCU2<;J6&PF79A
M@DW"4W5Q.*48W2L_K75/VH?A;^T#X,_:Z\#?#[4;B[US]F_XCV_P@^(,-RD"
MQ_\ "1V]MX9UU[[3#;SS&?13<WVI: ES.MO*VN>&]=M3"$MHY9?'_P!C_P#:
MJ^#]K\>/'?[(.K:Y_8GQHF\,^'/BIX8TC53!;6/CKPMJ%G?6FI0^%;DR$WVN
M>&7TM[G7-$D6._&E7,6K6,5Y8VFJ26'YB6>I1?LJ_M _ .T'A'XN>&?"O[5W
M[->E?LU?'#Q+\1?AOXK^'^E>)OVKOAYJ=Y\4/ _CZ2]\2VT,6L^(/B!/K7Q.
MT.Z$4\TB0?86-U<K"IKMM _8O\+?MF?'G]K#1Y?&'B3X7?%WX5^"/V5/'OP$
M^,'@ZX6R\1_"_P"(R6?QB33O$5K/%Y=]=:9-+8P66OZ)%=VMOJVF&2,RQ7D5
MI<VOL5N%L@PV>57C<1C\-D.*X4>99;F470Q57"XZ&98/(L37Q5'#U:T<3@\)
MFT,36Q6#I55BUE>98*K1:Q.'IT\5PX7BO/<5PY%X6A@:^>8;BV.79AETU5P]
M+$X*IEN*SS"X?"U:\*$L-BL5E4Z%#"XNK2>'_M/+\53K+ZM7G4H?NY^TU\<+
M#]G/X&_$;XU:IX=U'Q3H_P .O"VL^*=;TC1]0T?3]7GTC1]-N=0U"32CK=W8
MV-]J$<-L?L^FFZBN+UW$<!9_D/XC_MS?"RP\2?\ !(/]I#XW^-/!4&B^+M>^
M%WA#Q]X @UF+2]0\5^ ;)?%7AC6M,O+/7-/:9M'U;6H+A?[132+U"MD\=C=R
M3J9X:XS5?B3\3/C7^SU^UU^S)^TQK^H>$OVUO@#^S]\5+[Q_\.O$VI7-UX+^
M,'@4^"=?M]*^/'P+U1C'%J7A/Q+:I#_:FGQVLESX9UR673;QM/CGB@AZ7]MW
MX^ZGJW_!(;XX> O&-GLU!OV:?A_!HVK6UL;>5[I3X'=;#6+!SMAG<.S1WD*)
M$618I[1"XE.N19-4R/B3A&&,HJEFT/$'),)1Q>&Q<ZV%QV58J&4X[!XG!5*4
MEAL3@LPIU:M:ABZ;DJ^&E*A5A&=+%8:E&<YO#/N&^*_J%>GBLIJ<"9GB\3@L
M3A84<5@<SPN*S#!8O"XRE7C+$T,5@ITJ-/$8:HDJ-:$*]*52-2A6JS_MB? G
M1/@U^QA^QI^T?^R9X9TWX1_M;^'O$?[)?A7X>7WPQLQX4U'XP7/Q)E\-Z!XA
M^&OCG2- 2VM/B-HNO6FIW_B#6[?Q)8:Q=6MMI6I:@)X(&U%IOZ(-2UNP\/Z%
MJ.O^([VTTO3=%TF\UG6[^>01V.FV6F6<E[J5W-,ZKLM;2"WGEDD<#$,>\@;L
M5^(GQ*_8<N[W]CSX+_M%_LS_ !2^*_PP_:<^ ?P&\/?%3X1ZKJWQ/\;_ !&\
M W^LV_PJMI_$'A36?AQ\2];\7>#K/3?&>@2ZEX86^T72M(O-+AU..-+@Z2MS
MIL]63]NNY_; _P""<O[,OB$>'_$%G\0/VS?&NC_!;QSX5^&>A:QXCU^T\/\
MA#Q#J\_[3&K>#_#M@MSKE_H4WP[\!^*X;,VZWSZ6OBW1X+J>X>&1Y.O,\OK<
M095D]3#8W^T</EW$^>95FN.Q5.='-\O>9XG%YOA\-56(Q%=8C*:&693FN*P%
M=8Z5.ECIXK"2I8*,Z2Q'D97F%+AW,,W6(P<<NKYAPQDF:93@,+4IULIS!Y?A
ML+E=?$4WA\/1E0S2OF6:Y5AL=2^IJ=3!1PN)C4Q=2-5TOUE_9C_:*^'_ .U=
M\"_A[^T%\+I;V3P3\1](N=3T>+5(HH-5LGL=4O\ 1M2TO5;>"6>*VU#3M4TV
M]L[J%99!'+%\KNA#-YQ\ _VN+/X[_&+]H+X-V?PN\8^#=9_9L\2:+X/^(6M>
M(]4\(7.BW'B#Q)HEMXGT&#PO_86M:GJ.JV5]X<N[?4I;Z\LM,%F\HL9X#=)(
MB?"G_!.[X@Z7\+OVN/VSOV1[;PSXP\!^!?%FOVW[9/[.GAKQWX*U;X>ZC#X/
M^)SP:-\:?#NA^&]:L]/GMO#_ (2^*UE+=:9#96[6JP^)+@Q^6L6*[C]@T,_[
M<G_!7+!^[^T%\#<G/<_ #P\/8YR0??H,XKQLRR# X&7%\J="M+#83*\DSGA^
M=7$.<Z>"SS-<%3H+$3H-T,55H8;$XO UFI.FL;E]><4OX,/8R_B3'8Z'""=:
M@L3BLVSG)L_ITJ"4*F,R7+,=.M*A&NHU\+2K8G"X;&T5R1F\)CJ4)>ZU4E];
M_M!?M::=\ OBO^SO\)=0^&GC'QEJG[2_B_4/ ?@+6O#6H>%;?2-.\3Z-I%YX
MDU6V\4#6M9TW4-.T^T\-6%[JJ:A866JBX-NUE' +IH4?5F_;#^#.G?M:K^QA
MKVL3>'OC+J?PIT7XM^#K75Q;VVC^/-!U+5/$NE:EI/AB],[277B?P[_PC,VI
M:GH<MO%=7&C72ZGI@OH-.UG^S_C_ /;^4?\ #87_  27[?\ &4OQ,/?J/@'X
MV(Z9P.W;T/!->>_M$?LG>"/VP_VQ?VE?A]XAU74/!/C_ ,(?LT_LC?$?X(_&
M;PN?LGCWX,_%'1OB%^TM_8?C+PKJ4,EO>"V^TP0VWB'13<QV&OZ2'LYS!=1V
M5_9[9?DO#]; Y3B<TEBL'2Q?#F>8W%X["SG6EAL;A>)<+D^!QL\+4357!X6C
M7C/&X.@X5\315:>'J0Q,*%.K.89]Q!1S#-,+EJPN+J87B3),#AL%B81HPQ&"
MQ7#N*S;&X2&*@TZ6+Q-2@X83%5HU*5"LJ5.O"6'J5IT_U5^-WQ//P9^%/CKX
MK/X7U;QEIWP]\+ZUXRUS1-!O-)M-9G\/>&],N=9UR;3#K5WI^GW5];Z=9SS6
MUC+>VAO91' DT;.&J[\'_B&/BS\,/ ?Q/3P[JGA2U^('A31/&.G:!K=QIUSK
M&G:3XAL8]4TF+5&TFYO--BOY=.N+:>[MK.\NXK2:1[9KB1HC(WY,?#[]KKQY
M\0?@K^U5^Q3^U]I>E^!/VV/A3^S[\41J\%E$(?!W[1'PYF\$Z]I^D_'?X/F2
M*"'5='UJ-47Q;X<M%$_A?6WFMY+6R@,VGZ5^FG[+!#?LR?LZG>,GX%_"9B.Y
M!\":+QV[Y'X'K7A9KDU7)L).AC:--8Z&;0A1Q=&O*MA,;E5?*/KV$Q>"J0E]
M7Q.#Q<VJU#%TU>4'*A4C1KT<11H^YE.>QSG,(5<'6G]0EE,YU<'6H0I8K!9I
M0S9X+%87&1DO;X?%X:%Z.(PM1\L9J-:FYT:M&I5]_HHHKP3ZH_ '_@Z._P"4
M%'[<W_=LW_K8?[/M%'_!T=_R@H_;F_[MF_\ 6P_V?:* /JW]K+_@G#>?$SXW
MZ%^V'^RM\7+O]F+]L'PYIL>B7OCBVT.+Q-\._BWX:@A@@3PI\8O!)NK,:Y9/
M:6UIIPUJUG_M"#3[2P2:UOI='T"?2-W3/'W_  5?TC33H6O_ +/'[%OC/Q%$
MBVT7C_P_^T7\3_!OA.Y?RU1=1N/ VJ_!;Q)X@L4W9EGTZW\27C*"8H+QL+(?
MTS/;'ICOZ''<8_'N>U08YX+#D_Q-G&<XZGO]?ZU[_P#K-CJN%P>"S+"95G-'
M+J"PN GFN"=;%X/"IN4,'2Q^&Q6!QE3!492F\/A,55Q5##J<XX;ZO3DZ1\M/
MA?!T\7B\;EF+S3):V85GB<?#*L9"AA,9B6E&>*JX'$X/'8.&+JJ*5;%X:EA:
M]=QC/$.M.*JGXQ?&O]B+]LOXT_LRV_A+Q-\1?@1J?[1/BK]K3P/^TYX]UUY/
M'6D_"30M-^&&M>'+KP-\+_!-C!HFI^*K_1K'1/!OA;1;C4]7%A<RSQZSK4L<
M]_J*I'^@?A&?]K2_\537OC[PY\"O#?A+3/!VMC3]#\$?$?QGXNU/Q7X_N[FP
M71_[;U+Q!\)_"47ACPKI5A%JAEETR+6]4OKV^M6>SBM[)XKOZ>(&T8XSCW)Q
MTZM^G)Y'>D5023Z'C(Z9Z@@DG&>W'Y],,5G^,QN&IX3$X;*Y4:-?&XG#QAE]
M.E]6J9@L%]8CAG3Q*5*CR9;A*5&DX58X>E3FJ<Y3JU:TML+PW@\'B7BL/B\U
MC6J8?!X?$<^/=6.*IX&.-5">)]KA92JU7/,,56K554I.O5E#VD53I4J,?S5_
M8K_8EUKX3?L03_L8_M.Z7\-/B9X=OS\5=/\ $1\,7FN:CX;\7>'/BIXW\5^,
M=0T^[L-?T+1-1T>ZTH>)%L8+FVFNI?.L[?5+.YLKF-%CSO@W^S;^US\&/@9\
M4_V7=2^('P[^.'PRB\(^*O _[.?Q'\<^(?%/AWXK^%/!FMZ'>Z3X9\&_%VUM
MO"GB+2/&L/@:*YM]-L/%VB:MINJ:KHMA!#=Z+'<[9E_3X# QSQZG) /3N>W3
M/]:;C)PO&,]SD=1QSW//09&,D5IB>)LUQE;,:V*EA,1_:N:0SO%TJN#I2H1S
M:G5]I]>P=-54\!6J*/L*ZPU54\3A9/"XBG4I1I?5XP_"V583#Y90PT<7AUE6
M5U,EPU6EBYQKU,KJ49TG@L94=.2QM*#DZ]%XBDZN'Q*6)H5*=2515OQU\&_L
MV?$7]F_]C/\ 9H^%/Q#D\'ZQXB^ OA:V^%FH>(? NHZM>:'X@TN.+S-%U81:
MYHFD:AI+R26B6MS9RPWT:7D[RQ71CDCB$G_!+;X;?%'X0Z=^UE8>)IOA[K=U
M\4/C[XT^/?AFPT3Q+KL-SI0\;Z3H^G6'AK6QJ'A.&,VUM+H"1W?B/3!>"*65
ME.CR9A,GZT^*/#6F>,/#NK>&=8B\W3M8LY+.X"G]Y$6 :&YA8\I<6LZQ7%N_
M.R6*,D$#%?F%-:^.?V=/B-;SM'NFM'E%G<LLB:3XMT"611/%O0,J^;&J>=!S
M<Z9?QQ2A2$B>3@Q.?YC[7/:M6.$G#B;$T,5G$EA8QE*OA\PQ&9TYX;EJKZI3
M>,Q5>I.G24U.%1T4XPC3M[6'R#+JU#(J"EB85^&:&(H9,OK4E:EB<OI9;56(
M3I<N)G'"4*=.$ZBA*G.,:JC*3FGS7['?[.W[?/['_P"SQJWP0TJR_9-\>ZI_
MPFGQ3\:>%?%]_P#$KXL^'+'2KOXE^*]9\9BSU?PY%\(=:DU6VT+6M<N]AMM;
MTQ]2T^*"U(L;@27K_2?[+W[.7Q%\"Z;^U'IG[0(^'?C.#]HOXNZY\1=47PWJ
M.K:I9:EH'B/X7^!?AEJ'A?Q)INK>'-!@25[#P7+/<MIYGTV>VU@V4,$ LO-N
M/JKX>_$OPM\2M(34] OE^U1HIU+1KAPFJ:5.PPT5W:^;N>(L3Y-Y"&M;E?FB
MDW;T7T0*N./\YP<]L<>F,]\UW8_B7,,SGF5>M3RV%?-\51QN-Q.#P,,)7K8C
M#UXXFE4A5IXJHJ"A7IPJ\E"%.#FDW%247#Q,%PI@,N_LZC&MF=6CD^'KX/ 8
M3&8SZQAJ%#$8>IA:L)4982E[=SH5)TN:M*HU"T4^1N,_@#]@G]B!/V+OAUXK
M\&7?C_4_B7JFI>);G2_#'B/6?M3WWAKX&>$+W5K+X'?"6"2Y=W;3OAYX6U&X
M61D)BG\1:WXBOHF,%U"B?)GP2_8%_:>^&OP[_9__ &>?$NL_ [6/@1\&OVNO
M%G[0VL#1/%'CNT\3>+?!(\:>+OB7\*_ ']BWO@8Z1;3^!/B+XBTCQ)JTEQJT
MVG:[!X.T;3K:/3Y+J]NA^V9!QQ[]>0?K_/\ 3BO)OB?XL;1CX/\ #FFW[VNO
M>,_&&@:39_9W NXM,@U*WO==NP#O"VXT^WDLI'= A:]5.I.*?%>=+$9IC:]>
MC7Q&;8FAC<;4K8:E-O%X?#XW!X?$T(TYX>GAJU*EF>-4'1IN$9UW65-5(Q9*
MX,R1T<LP>'H5L-0RK#U\+A84,55BOJF(Q.#QN*P^)G.&(GB*%>MEV$E6C5FI
M5*=%4I3=.4HGR-_P5!_9XOOVD?V/O&GA30-6TSP_\1?"/B7P!\3OA1XNU87
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M-QPN'A/#2KTZ.*K1=-2Q.(PN#JXBK/ZM1I+YW_:P_9<^*GQ#^/\ ^R9^T[\
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>NR)OG90VU=S*52=U_P /^J0M5NK?-/\ )O\ ,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>brtx-20230414.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaGOebP9z5Z8+ekhvWB5bUl6by8r0YaIwSwQAndmEZMC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:BRTX="http://biorestorative.com/20230414" elementFormDefault="qualified" targetNamespace="http://biorestorative.com/20230414">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://biorestorative.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230414_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="brtx-20230414_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>brtx-20230414_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>brtx-20230414_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://biorestorative.com/role/Cover" xlink:href="brtx-20230414.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://biorestorative.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140062389504800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 14, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 14,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIORESTORATIVE
THERAPIES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001505497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-1341024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40
    Marcus Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Melville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">760-8100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BRTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="brtx-20230414.xsd" xlink:type="simple"/>
    <context id="From2023-04-14to2023-04-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001505497</identifier>
        </entity>
        <period>
            <startDate>2023-04-14</startDate>
            <endDate>2023-04-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-04-14to2023-04-14">0001505497</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-04-14to2023-04-14">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-04-14to2023-04-14">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-04-14to2023-04-14">2023-04-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-04-14to2023-04-14">BIORESTORATIVE THERAPIES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-04-14to2023-04-14">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-04-14to2023-04-14">001-37603</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-04-14to2023-04-14">30-1341024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-04-14to2023-04-14">40     Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-04-14to2023-04-14">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-04-14to2023-04-14">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-04-14to2023-04-14">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-04-14to2023-04-14">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-04-14to2023-04-14">760-8100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-04-14to2023-04-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-04-14to2023-04-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-04-14to2023-04-14">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-04-14to2023-04-14">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-04-14to2023-04-14">Common     Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-04-14to2023-04-14">BRTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-04-14to2023-04-14">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-04-14to2023-04-14">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" "FBHY6_E$S>5,$  "#$   &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)V8;W/B-A#&W]^GT+B=SMU,$BQC($F!&4)(C[D[0H'F^F?Z0M@"-+$E5Y8A
M^?9=&6+3.[-FFA?!-M['/Z]6STIT=TH_IQO.#7F)(YGVG(TQR6VCD08;'K/T
M2B5<PC<KI6-FX%2O&VFB.0OSH#AJ>*[;;L1,2*??S:]-=;^K,A,)R:>:I%D<
M,_UZQR.UZSG4>;LP$^N-L1<:_6["UGS.S6_)5,-9HU )1<QE*I0DFJ]ZSH#>
MWGF^#<CO>!)\EQX=$_LJ2Z6>[<DX[#FN)>(1#XR58/"QY4,>158)./XYB#K%
M,VW@\?&;^D/^\O R2Y;RH8J^BM!L>LZU0T*^8EED9FKWD1]>J&7U A6E^7^R
MV]_K^PX)LM2H^! ,!+&0^T_V<DC$44"S?2+ .P1X.??^03GE/3.LW]5J1[2]
M&]3L0?ZJ>33 "6E'96XT?"L@SO2':LMUMV% REYH!(>PNWV8=R)LD.@K0OT+
MXKE>\[_A#2 H,+P"P\OUFA@&^6NP3(V&@?J[BFBOX%<KV.J]31,6\)X#Y9ER
MO>5._Z<?:-O]&>%K%GQ-3+U_KX(,:M&0Q6O"J^#P\.O+3PB$7T#XJ,H ",*<
MXB%BZRH*/'[%HI0C'*V"HW5>,J9<"Q62D0P)%%]E7G"EHHSJZJA=H+51P9$T
MPKR2!Q%Q,LGB975MXQJN2R^;G;:+\70*GLXY/#.^%K:R(6<3%E<F"M>Y&S_.
M1O/%XVRP&#^-WBT^CF:#Z7@TOR#CR? * ;TN0*_/ 1W"L&H6D;$,^0OYQ%^K
M4'$E%_+7<EO^30?!NBFP;L[!6K 7,@Z!3:Q$P'([/SVZN&+3O:1-G[J>C^!1
MM[1/]QS L0R43I3.V2[(W,!T($J3H<H@H9!7%5:.>HWZY F#//)X>@[D( S!
M&=.+MP/R&>XCC[*:#)?TW7<$_KXP#4V*W&MHK1AJV0<H:N/?H0[M&21RH7:R
M$A.7^\*CK8@BE*WL 11W\6_9BE&>:K45,JC.(ZXY^0-#*SL#Q:W]6[2I2@U,
MXS]%<KKT<$5*.SXV@VG9+2AN\OD0#F#)>!H%%WC?;M(/&$K9'2AN[9]5 %F9
M;I3$VD.-"+2&RVOJNAA1V1\H;NQ?M3"&2TA-'&?R8&YI)14N5-?<:=D)*&[@
M<Q6)0!@AUS"]#;1X%E7RX"JU/&4+H+AC3S6_#" ]'&;8?@T&RR!8+3ZN5B?&
M#]>K(_-*\_=P>_Z.;)RF&9#5 =;(U@*6QN_A+KT0!A9":D6H]W[Y@<QYD$&]
M53;U&B5;GTKFGC\W*GB^(#^Z5[;5DX1ILF51AA(?[0-PPUYH%MK*F[_&2U59
M=S4"=[/%[QA)Z?8>[LQOR2*CEV##Y)J?7+K5"$T&\_O!KQA3:?/>638_BKE>
MVRS] @IF8\TC8;)Z6/_GEJ!QM*6TVW-H]/#$E$1\!4+N50<L6^]WO/L3HY)\
ME[E4!O:L^>&&,Y@&]@;X?J64>3NQ&]?B=X?^OU!+ P04    " "FBHY6GZ ;
M\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV
M0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\
MX<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)
M8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@
M7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-
MAF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY
M!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"P
MU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1
M%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]
MFZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7
M>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[
MJ,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P
M/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRK
MZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#Q
MNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q
M_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M    " "FBHY6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_
MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+
MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D
M5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/
M['X 4$L#!!0    ( *:*CE:JQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN
M>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>
M]I3<V;K<7187XM.!Z)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L
M <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q
M&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1F
MEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C
M5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V
M1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
M    " "FBHY6)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1A
MLIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ
M$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!
M4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%0
M2P,$%     @ IHJ.5F60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN
M>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%
M3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#W
MR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?
ME.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH9
M0]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTC
MR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_
M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " "FBHY6!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *:*
MCE:#F/=>[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( *:*CE:97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ IHJ.5OY1,WE3
M!   @Q   !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( *:*CE:?H!OPL0(  .(,   -              "
M 9<,  !X;"]S='EL97,N>&UL4$L! A0#%     @ IHJ.5I>*NQS     $P(
M  L              ( !<P\  %]R96QS+RYR96QS4$L! A0#%     @ IHJ.
M5JK$(A8S 0  (@(   \              ( !7!   'AL+W=O<FMB;V]K+GAM
M;%!+ 0(4 Q0    ( *:*CE8D'INBK0   /@!   :              "  ;P1
M  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( *:*CE9E
MD'F2&0$  ,\#   3              "  :$2  !;0V]N=&5N=%]4>7!E<UTN
9>&UL4$L%!@     )  D /@(  .L3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biorestorative.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>brtx-20230414.xsd</File>
    <File>brtx-20230414_lab.xml</File>
    <File>brtx-20230414_pre.xml</File>
    <File>ex1-1.htm</File>
    <File>ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "brtx-20230414_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "brtx-20230414_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "brtx-20230414.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "BRTX",
   "nsuri": "http://biorestorative.com/20230414",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-04-14to2023-04-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://biorestorative.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2023-04-14to2023-04-14",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://biorestorative.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-23-012377-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-23-012377-xbrl.zip
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M<IS^.WGN/!&WB[W@835LA:2A# \5F[T^8%0,$D$^3JQ+7.4-#>NK9$:YNU>
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MM4<)G-1$#AX?KR9ISS/03,NZ6B<MO"1I*_[OHJOQ!.$I ;-XC4^B4^C.7IK
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M>;3?J@\O,#?V#O\?S@#^"VLQL"RS.L\^/ICE(.1@-!M:2QN4_):&]S9<1=I
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MOG"MX56P7.H@9KML.!R6WGL>/7R&#WO\[<EU[\.%\-/91;SR?.-W3B>/CY^
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MP&;L\<OO8D4=\'&.-889XJ'O&TG3R6W:'6[1PL@)!M>=RMS?T/MX0P5X]*K
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MNP["Y%LC=\INO:C6N&+ST1A%1M%S\>650<"4*FI\1<EJAM"&0Z>^\ML/FG%
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M44_4#D)XM'>>#X<:5*?MI[>U>^=T8L."F$9,/N;Y1N^73^($#)(Z/J*7F_,
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MI7/D_P8Y=[<_>GDSMWV4^-?R<)H]U77IGC2A@SYNR#GYL8O63I$GCQ 1'$Q
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M?UOD&2(WT,/R6SW0^I<"Z!QPESYN%:H>W2*F8Z2R?B9G@UN1KY;D0F6?,JU
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MG4;(J^$ZM\C7%7)[NY7D!T. #M.I'_C,=%1-3R240_0+PSID$W?GJ9T4:>Y
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M9_ M68V!=1CY(!\>=_L?8"I=^ 7\?U@1? R<_^'I"1QP6NO?8=1JK8NKR^^
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MW^-"H,1W^R<B[C!@??,>X9CHACSN?^AK<?ZS^XG^K[IWX #C)NB7R=?@I)[
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M7S "F0PL+B(^J829ZA:F6F+.?! N^A<T\>8Z#E:7#LGWTF8IF).Z3/0\I%
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M>N?%7KJ!9PA/^<5WN3<'67RE[Z'H:O.V9H0#_"ZWQAR;XP@IB+R-VQLV&^.
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M%^<FR6!+&=*)K"#:,PSV@6&@Y*/&'8TH6(0::^[&*4L$_$'+A)\D&46>0'N
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M+ZA[YCQKA:MA > MMD_M#'TP]L].]'T6@7V:'@]D;R<C?5Y@D>;67K]4>VF
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MA:3XR8R:3DH,T%&@878O#4L4U3"F]>5'P-S<\(#./!P#%][@N:$SR\MY 3[
M/=M!OPY& 1H'>*Z'7%X6 U@6NE-@M@->H9MAQK8>*;C!#/=\=R"2!X2)!29O
MFW0@MB$VL!+[X.]MZ ,ST^VA6XK?8345A]DFWDM2/ ]SBD-X$D14T@V<.Y$G
M'>=')QE3?"L&0MC>W.C1@3@?HA/:!6YTT>\6F+F[T(%6',4Q$8%_9Q*[!&1
M0Q]WFGCW'0P^]:N)X5]?;M^_9K90(SSIP202!E'>D07OA -(I@B.W!F>WJX<
M5* $:3KMGQ#^^((*.MJWA'1#_*ZH[IX./TL4[(MR#G@(T08%A!$QBA,;1#@&
M8-H(@C)J@?ZAO\ ZX#O90!3 M;!F(SJ!UJHV$L#[H*6VI[M"N<1@)J<0FLG(
M#)\LCZ0YM=O<P)>;*2#S(.5AZH5OG...B/2LP!DKX)/0F&T7'F@M,IMH:A]Q
M@X^&2-[),.LP/7R$JDG[#%@EGDXQRO+O+Q0)P"DD$N1ZT11L3PP$0?LR320
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MYC(#2ZWO9/Y;*)UV3\Y;A2]?7);\/U!+ 0(4 Q0    ( *:*CE9668$V5P,
M ,L,   1              "  0    !B<G1X+3(P,C,P-#$T+GAS9%!+ 0(4
M Q0    ( *:*CE: ^6?Z_@H  ("&   5              "  88#  !B<G1X
M+3(P,C,P-#$T7VQA8BYX;6Q02P$"% ,4    " "FBHY6^A2RGUT'  #A5P
M%0              @ &W#@  8G)T>"TR,#(S,#0Q-%]P<F4N>&UL4$L! A0#
M%     @ IHJ.5L^)X3#VKP  D(,$  D              ( !1Q8  &5X,2TQ
M+FAT;5!+ 0(4 Q0    ( *:*CE9$_8<C_ H  .]#   )              "
M 63&  !E>#4M,2YH=&U02P$"% ,4    " "FBHY6T9V-VN<5  #NH0  "P
M            @ &'T0  9F]R;3@M:RYH=&U02P4&      8 !@!L 0  E^<
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
